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ABSTRACT
Over the last decade, the innate immune system has been the subject of extensive
research. Often overlooked by the robustness and specificity of the adaptive immune
system , the innate immune system is proving to be just as complex. The identification of
several families of pattern recognition receptors (PRRs) has revealed an ancient yet
multifaceted system of proteins that are responsible for initiating host defense. A wide
array of pathogens, from virus to bacteria, is detected using this assortment of receptors.
One such family, the Toll-like receptors (TLRs), has been at the forefront of this
research. To date, 10 TLRs have been described in the human genome. Activation of
TLRs leads to the induction of immune-related genes that ultimately control the response
of the host. However, the signaling pathways emanating from activated TLRs and other
PRRs are not fully understood. In particular, the pathway leading to the activation of
interferon regulatory factor 3 (IRF3), a transcription factor crucial for the induction of
type I interferon, remains undefined. IR3 activation occurs as the consequence of viral
infection and through the activation of TLRs 3 and 4 by dsRNA and lipopolysaccharide
(LPS), respectively. The focus of this research is to describe components of the IRF3
activation pathway, partly through the analysis of TLR signal transduction.
IR3 normally resides in the cytoplasm of cells. Upon infection with certain
viruses and bacteria, IRF3 is activated though phosphorylation at its C-terminus.
Phosphorylated IRF3 homodimerizes and associates with co-activators CBP-p300. After
translocating to the nucleus, the activate IRF3 complex induces the activation of type 
interferon and interferon related genes. Little is known about the pathways that lead to
the activation of IRF3 , especially the kinases involved. In this study we report that the
non-canonical IKB kinase homologues , IKB kinase epsilon (IKKE) and TANK-binding
kinase- l (TBK1), which were previously implicated in NF-KB activation, are also
essential components of the IRF3 signaling pathway. In particular, mouse embryonic
fibroblasts from TBKI deficient mice fail to activate IRF3 in response to both viral
infection and stimulation with LPS or poly (IC), a dsRNA analog. Thus , both IKE and
TBKI playa critical role in innate immunity and host defense.
In addition to viral infection, IR3 activation also occurs via the activation of
TLR3 and 4. TLRs signal through a subfamily of Toll-IL- Resistance (TIR) domain
containing adapter molecules. One such adapter, MyD88 , is crucial for all TLRs , with the
exception of TLR3. MyD88 participates in a signal transduction pathway culminating in
the activation of the transcription factor NF-KB. Studies from MyD88-deficient mice
reveal that both TLR3 and 4 stil are capable of activating NF- , although with slightly
delayed kinetics. Another aspect of the MyD88-independent signal transduction pathway
is the activation of IR3. A second TIR domain containing adapter molecule called
Mal/Tirap was discovered and originally thought to mediate the MyD88-independent
pathway. However, Mal-deficient mice were found to be defective in both TLR2 and 4
mediated NF-KB activation. We hypothesized that other TIR domain containing adapters
could mediate this MyD88-independent pathway of TLR3 and 4 leading to the activation
of IRF3. Two additional TIR adapters were discovered, TRIF and TRAM. TRIF was
shown to mediate TLR3 signal- transduction. In this study, we report that both TRIF and
TRAM mediate the activation of the MyD88-independent pathway in response to
LPS/TLR4 activation. Unlike any of the other known TIR domain containing adapters
TRAM appears to be restricted to the LPS/TLR4 activation pathway while TRIF plays a
role in both TLR3 and TLR4 pathways leading to IR3 target gene expression.
Our studies revealed that TRAM could be - acting upstream of TRIF in the
LPS/TLR4 pathway. To this end, we sought to determine the localization of TRAM
within the cell. We found that TRAM localizes to the plasma membrane. TRAM
localization is the result of myristoylation since mutation of the predicted myristoylation
site (G2A) resulted in the re-distribution of TRAM from the membrane into the
cytoplasm. Reconstitution of TRAM-deficient macrophages with TRAM G2A is unable
to rescue LPS/TLR4 signal transduction. Thus, myristoylation and membrane association
of TRAM are critical for LPS/TLR4 signal transduction.
The data generated in this dissertation extends our understanding of the signaling
pathways of the innate immune system. Indeed, the molecules and pathways described
herein could prove to be beneficial targets for ameliorating symptoms of disease, both
autoimmune and pathogen-associated. Finally, the research described here will spur
fuher insight into the complex signaling pathways of a once ignored arm of the immune
system.
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CHAPTER I:
INTRODUCTION
1.1 Innate Immunity
The ability of an organism to defend against invasion and disease caused by
pathogens depends upon a functional immune system. The immune system of vertebrates
consists of two components: innate and adaptive. These two "arms" of the immune
system work closely together to combat disease, infection, and re-infection. The innate
immune system is generally considered non-specific, quick acting, and represents the first
line of defense against pathogens. In contrast, the adaptive immune system is extremely
specific, exhibits immunologic memory and is triggered only if the pathogen escapes
destrction by the innate immune system.
The innate immune system relies on several different modules working in unison
to destroy and eliminate potential pathogens. Mediators of these modules are both cell-
based and/or depend upon the direct action of effector molecules. Although a wide
variety of cells are ultimately involved in innate immunity, in general, three key cell
tyes can be described based upon their collective activities. These groups are 1)
macrophages, dendrtic cells (DCs), and neutrophils, 2) y8 T cells and B cells , and 3)
Natural Kiler (NK) cells.
Macrophages, DCs, and neutrophils
Resident tissue macrophages are one of the first cell types to contact a pathogen
once it has crossed the epithelial barrier. The next events involve the recruitment of a
large number of neutrophils to the site of infection from the circulation. Using a variety
of surface bound receptors mannose binding receptor, the macrophages and
neutrophils are able to discriminate between self and non-self. Upon encountering a
pathogen, these cells begin the process of phagocytosis. Phagocytosis involves the
engulfment of a pathogen into an intracellular vacuole known as a phagosome. As the
phagosome matures , it becomes acidified. This maturation, combined with the release of
lytic enzymes and powerful toxins such as nitric oxide , proceed to dismantle and destroy
the pathogen. Phagocytosis provides two basic functions. First, it results in the
elimination of most, if not all , of the pathogen at the site of infection. Second, it results in
the production of signals and attractants (cytokines and chemokines) that are involved in
the inflammatory response and recruitment of DCs. It is here, at the site of antigen
uptake, that DCs also encounter microbial products that provide a "danger signal"
(discussed below) that allows for effective T cell priming. After antigen uptake, DCs
migrate into the lymphatic system, and interact with T cells to initiate the adaptive
Immune response.
r8 T cells and B- B cells
The y8 T cells and B- 1 B cells are a second group of cells involved in the innate
immune system. These cells represent more primitive versions of their adaptive
counterparts , the T and B cells. However, unlike mature T and B cells , y8 T cells and B-
cells undergo limited receptor rearrangement. This leads to receptors of limited
diversity. In addition, both cell types seem to have a distinct location in the body. y8 T
cells are primarily found in most endothelial layers while B- 1 B cells are generally found
in the pleural cavities. What makes these cell types innate in nature is their early response
to infection when compared to T and B cells. In addition, these cells are present early on
in ontogeny, and thus playa crucial role in preventing disease before the development of
a fully functional adaptive immune system.
JVaturallriller cells
The third and final group of cells described here are the Natural Killer (NK) cells.
NK cells are derived from the common lymphoid progenitor cells in the bone marrow.
They are larger than T and B cells and contain large cytotoxic granules in their
cytoplasm. NK cells are thought to be involved in protection against both intracellular
pathogens and cancer. NK cells possess two classes of receptors that control the release
of their cytotoxic granules. These receptors are classified as either activating or inhibitory
receptors. The activating receptors recognize certain glycoproteins present on cells. The
inhibitory receptors recognize major histocompatability complex (MHC) class I
expressed on cells. This balance of positive and negative signals is normally skewed
towards a negative signal on healthy cells that are expressing normal levels of MHC I.
Under these circumstances, the target cells are left untouched. However if altered or
lower expression of MHC I is expressed, as is often seen in infected or cancerous cells
the positive signal is stronger and cytotoxic granules are released by the NK cell thus
kiling the target cell. Although resting NK cells are capable of kiling a target cell, they
can become activat d. An activated NK cell becomes more sensitive and gains enhanced
cytotoxicity. The activation of NK cells is tightly linked to the cytokines and interferons
produced by activated macrophages. IL- 12 and type I interferons (IFNa/f) released by
macrophages and dendritic cells activates NK cells, which helps control the infection
-,-
before an adaptive immune response can be mounted. Moreover, activated NK cells
produce larger amounts ofthe type II interferon, IFNy.
In addition to the cellular based facets of the innate immune system there is an
important component that is based upon effector molecules. These include the
complement system , antimicrobial proteins and peptides , and "natural antibodies." Innate
effector molecules are extremely important to an organism s health. In contrast to
cytokines and chemokines, which act mainly to enhance cell-mediated immunity, these
effector molecules provide immediate antimicrobial properties and assist in discerning
pathogens from host constituents.
Complement
A key effector system of innate immunity involves the complement system. The
complement system is a class of over twenty soluble and membrane-bound proteins.
There are three major pathways leading to the activation of the complement system (Fig.
1). Activation results in the orchestrated enzymatic cleavage of many of these plasma
proteins. Some complement protein products are directly involved in pathogen
destruction, such as the C5-C9 membrane attack complex. Other proteins bind to and
opsonize pathogens , thus enhancing the phagocytic abilities of phagocytes. Besides these
direct effects upon pathogens , activated complement proteins and cleavage products can
also act as chemoattractants causing the vasodialation of surrounding blood vessels and
aiding in the recruitment of phagocytes.
Antimicrobial proteins and peptides
Other effector molecules of the innate immune system consist of antimicrobial
proteins and pep tides. These effector molecules are present in bodily secretions of the
epithelial linings of the body and provide a means of defense against potential pathogens.
A prime example of this can be seen in the lungs. The lungs represent an organ that is in
high contact with the outside world. The vast surface area and amount of air exchanged
over the airway epithelium exposes the lungs to a variety of microbes and pollutants. It is
here that a plethora of antimicrobial proteins and peptides can be found. For example , the
contents of the epithelial lining fluid (ELF) contain lysozyme and lactoferrn, both
proteins with general bactericidal activities (1). Several cationic peptides ofthe defensin
and cathelicidin families are also present in the ELF. These peptides have selective
membrane permeabilizing activity. Resident alveolar macrophages work in conjunction
with these antimicrobial proteins and peptides to provide immediate defense against
pathogens in the lung.
JV atural antibodies
A final category of innate effector molecules in the body is the so-called natural
antibodies. These natural antibodies are generally of the IgM class and comprise a large
amount of the circulating IgM found in humans. The exact origin of the antibodies
remains unclear, but their low affinity for many microbial pathogens and lack of
diversification by somatic hypermutation result in innate-like characteristics. For
example, these antibodies have been described to bind to phosphatidylcholine on the
surface of bacteria, such as Streptococcus pneumoniae and promote clearance before
they can become harmful (2).
1.2 The Danger Hypothesis
The key to an effective immune system is the ability to discriminate between self
and foreign antigens. The adaptive immune system must ensure that responses to self-
antigens are kept to a minimum. This is mainly accomplished during the stages of
lymphocyte development. Self-reactive T and B cells are eliminated during maturation in
the thymus and bone marrow, respectively. It is in these compartments that T and B cells
are exposed to self-antigens. Any self-reactive lymphocyte is programmed to self-
destrct. Escaping from these developmental checkpoints are lymphocytes reactive
towards antigens expressed exclusively in certain tissues and not in either the thymus or
bone marrow. However, these potential autoreactive lymphocytes are usually quiescent.
This is explained by the lack of a "second signal" required for lymphocyte activation.
This lack of a second signal leads to tolerance and a state of anergy among the
autoreactive lymphocytes.
The second signal or co-stimulatory signal comes from the detection of microbes
or possibly tissue injury during the innate immune response. The mechanism of detection
wil be discussed later. For now, the second signal is dependent upon the upregulation of
surace molecules CD80, CD86, (also called B7 molecules) and CD40, on the
antigen presenting cells (APCs). This activated APC travels to the lymph nodes and
presents the antigen on either MHC I or II to the cognate T cell. T cell receptor (TCR)
ligation (signal 1) and co-stimulatory CD28 or CD40L ligation (signal 2) results in the
formation of an effector T cell.
It is this second co-stimulatory signal that provides the basis for the ' danger
hypothesis . The danger hypothesis , coined by Polly Matzinger, is the result of years of
immunologic observations by a number of people (reviewed in (3). The danger
hypothesis , in its simplest form, states that the immune system responds to challenge or
antigen only if the threat is determined to be dangerous. At its basis, the danger
hypothesis implies that the immune system is not concerned with discriminating between
self and non-self, but is rather concerned with sensing the presence of danger. In the case
of infectious disease, the danger signal comes from the pathogens themselves. To this
end, the innate immune system has evolved a variety of receptors to detect pathogens or
pathogen associated molecular patterns (PAMPs). These PAMPs are usually molecules
that are crucial for the existence of the organism or its virulence.
1.3 Pattern Recognition Receptors (PRRs)
The ability of an organism to detect pathogens and their P AMPs is crucial for an
effective immune response. Over the past decade, intense research has been underway to
decipher the mechanism of this action. This research has led to the discovery of a variety
of proteins that serve this function. Along with these discoveries , much interest has been
focused on the signaling pathways that emanate from these receptors and ultimately lead
to the transcription of pertinent molecules involved in host defense. Three such families
wil be discussed here: the NACHT (domain present in NAIP , CIITA, HET-E and TP1)-
-1-
LRR (leucine-rich repeat) family (the NLR/CATERPILLAR family), cytoplasmic RNA
helicases , and the Toll-like receptors (TLRs).
JVLR Family
The recently identified NLR family is responsible for detecting intracellular
pathogens. The NLR family consists of many members in humans (reviewed in (4)). At
its core , as with the TLR family, is the presence of a LRR domain. The LRR domain is
thought to serve as the recognition site for the P AMP , although direct ligand binding has
not yet been demonstrated for this family of PRRs. A second conserved domain is the
NACHT/NOD (nucleotide oligomerization) domain. The NACHT domain is present in
all NLR family members and serves as an oligomerization and activation domain. This
allows two or more of the same NLR molecules to come together. Finally, the third
domain, located at the C-terminus , determines what type of signal transduction pathway
the individual NLR will activate. These effector domains occur in three varieties: a
caspase recruitment and activation domain (CARD), a pyrn domain (PYD), or a
baculovirus inhibitor of apoptosis repeat domain (BIR). The CARD and PYR domains
are thought to initiate signaling cascades through homotypic interactions with other
CARD or PYR domain-containing molecules. The only NLR to posses a BIR domain is
NAIP. Recently, the signaling pathway initiated from the BIR domain of NAIP was
shown to regulate caspase- l activation (5 6).
5":;
RNA helicases
The RNA helicase family represents another family of PRRs that also surveys the
cytoplasm of cells. In this case they act to sense viral infection by the detection of
dsRNA. The family consists of three members: retinoic acid-inducible gene (RIG-
I),
melanoma differentiation-associated gene-5 (Mda-5), and Lgp2 (7). All three of these
proteins contain a DExD/H box RNA helicase domain which binds and unwinds dsRNA
in an ATP-dependant manner. However, only RIG-I and Mda-5 contain CARD effector
domains. As a result, these two RNA helicases are capable of inducing type 
1 interferon
(IFN) (7, 8). In fact, RIG-I is required for induction of type 1 IFN in response to
Newcastle disease virus (NDV) and Sendai virus (SV), both ssRNA viruses. Lgp2
, the
newest family member, does not contain an effector domain. It is thought to act in a
negative feedback loop by binding and sequestering dsRNA from RIG-
lor Mda-5 (7, 9).
In this manner, Lgp2 serves to limit the overproduction of IFNs, which could become
harmful to the host.
Toll-like Receptors (TLRs)
TLRs were originally discovered using Drosphila melanogaster as a model
organism (discussed below) (10). This ultimately led to the search for TLRs in other
species. The mammalian TLRs were discovered as. the genomic data base 
expanded
during the mid 1990s (11 12). In 1997 , Medzhitov and colleagues reported that "hToll"
(TLR4) was capable of initiating an inflammatory signal upon transfection into HEK293
cells (13). This was subsequently followed by a rapid number of publications linking
TLRs to responses to numerous biological agents including lipopolysaccharid
(LPS),
;:1
mycobacterial lipoarabinomannan, bacterial lipopeptides, CpG-rich DNA, polyI:C
flagellin and many more (14)). There are now at least 13 known TLRs; TLR11 , 12 and
13 are present only in mice.
TLRs are characterized as being type 1 transmembrane proteins with extracellular
LRR domains and an intracellular "Toll-Interleukin (IL)- 1 Resistance" (TIR) domain
(Fig. 1.2). As with the NLR family, the LRRs of TLRs are thought to serve as the ligand
recognition domain. The intracellular TIR domain of TLRs, as with the IL- IR and IL-
18R, represents the effector domain. Over the last five years, a great deal has been
learned about the proximal signaling events of TLRs and wil be discussed below.
. The subcellular location of individual TLRs is also an important aspect of their
biology. For instance, the nucleic acid sensing TLRs (3 , 7, 8 , and 9) all reside in the
endoplasmic reticulum (ER) and analogous endosomal compartments. Bacteria and
viruses that use this pathway to gain entry into the host or are taken up by phagocytosis
are detected in these compartments. Other TLRs, such as 1 , and 6 can be found on
the cellular membrane. Here these TLRs can sense products that are often shed from
bacteria, such as lipoproteins , LPS , and flagellin, or viral fusion proteins such as theRSV
F protein (Fig. 1.3).
The ability of individual TLRs to discriminate between invading pathogens is an
important determinant of the unique gene expression profies activated by different
microorganisms. Whereas the specificity of microbe detection begins with the ligand-
recognition features of one or more TLR, the discovery of a family of TIR domain-
containing adapter molecules (defined below), including MyD88 (15), Mal/TIRAP (16
17), TRIF/TICAMI (18 , 19), TRAM/TIRP/TICAM2 (20-22), and SARM (23), suggest
that the outcome of pathogen-induced recognition also depends on the TLR-restricted
utilization of these molecules, alone or in combination, to drive a stimulus-specific
response. Here I wil focus primarily on TLR4-dependent recognition of LPS and
receptor-proximal signaling events , since this TLR is the focus of my Ph.D. studies.
1.4 TLR4 and LPS
Recognition of LPS is medicated by TLR4, which functions in complex with MD-
2 (see below). At the outset of my Ph.D. studies in 2002, transduction of LPS signaling
was known to depend upon the constitutive association and/or the recruitment of at least
three of these adapter molecules to the intracytoplasmic TIR domain present in both
TLR4 and the associating adapter molecules , MyD88 , Mal/TIRP, and TRIF. These
adapters provide a structural platform, to which various downstream kinases are recruited
and downstream signals propagated, culminating in the induction of pathway-specific
transcriptional responses.
CD14 andLBP
Until 1990 , the prevailing wisdom was that LPS activated immune cells through a
non-specific mechanism that involved the spontaneous intercalation of lipid A into the
mammalian lipid bilayer. The discovery of lipopolysaccharide binding protein (LBP)
ultimately led to the refutation of this concept. LBP is a blood-borne protein that is
produced in the liver (24) and has the properties of an acute phase reactant (25). In
addition to the liver, LBP is produced in the lung, where it has numerous proposed
important physiological and pathophysiological activities , including a role in ARDS
. --- ---
nosocomial Gram negative pneumonia, asthma, and pneumococcal disease. LBP has
opsoni activity, but its importance as a protein involved in LPS responses lies with its
abilities to accelerate the binding of endotoxin to CD14 (26). Indeed, LBP is probably
best thought of as a lipotransferase that enhances LPS activity by moving LPS onto
CDI4. For example, studies in the LBP knockout mouse demonstrated that LBP
enhances the sensitivity to LPS by approximately 300-fold (27). The importance of this
observation is that in the absence of LBP, knockout animals are hypersusceptible to
invasion by otherwise harmless numbers of Gram negative bacteria (28, 29). This
sentinel function ofLBP is shared by CD14 (30).
CD14 was initially discovered as the receptor for LBP-bound LPS , and is central
to mammalian responses to endotoxin. CD14 is present in two forms: a GPI-linked form
and as a soluble proteolytic fragment found in blood (referred to as "soluble CD 14" or
sCDI4). Soluble CD 14, functions to enhance LPS responses in cells that do not
ordinarily express CDI4. Over 1400 publications have documented the importance of
CD14 in LPS responses. CDl4-deficient mice, engineered by Goyert et al. (31) and
Freeman et al. (30), are relatively insensitive to LPS. The presence of CD14 shifts the
LPS response curve by 1000- fold. Golenbock et al. have found that the f32 integrns
CD 11 b/CD 18 , can partially substitute for CD 14 (32). The ability of f32 integrns to
replace CD 14 as an endotoxin enhancing protein is nearly complete when macrophages
encounter LPS as an insoluble aggregate, such as a whole bacterium (30).
CD 14 has no intrinsic signaling capabilities , as it lacks both a transmembrane and
cytoplasmic domain. Furthermore, a variety of studies have formally demonstrated that
CD14 could not be responsible for some of the unique properties of the LPS receptor
, -
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especially the ability to discriminate between closely related lipid A analogs (33). As a
result, the existence of a transmembrane signal transducer, present on the surface of cells
and as a major part of an LPS receptor complex, was hypothesized (33). It was believed
to be the binding portion of the receptor, analogous to the IL-6 receptor and its associated
gp130 signal transducer (34).
An alternate hypothesis that was developed during the 1990s was that the function
of CD14 was to internalize LPS, which was subsequently shuttled to the Golgi apparatus.
The nature of the movement of LPS to the Golgi seemed to represent a unique biological
event, as none of the known membrane constituents, in particular CD 14, were then
thought to accompany LPS to the Golgi ((35); we have subsequently demonstrated that
this is untrue). The implication of this work was that signaling did not begin on the cell
surface. This hypothesis has not stood the test of time, as LPS signal transduction has
clearly been shown to be initiated on the cell surface in cells that express abundant CD14
and TLR4/MD- (36). However, in some cells, such as epithelium from the
tracheobronchial tree , the concentration of TLR4/MD-2 on the surface may be minimal
and thus , LPS transit to the Golgi , where TLR4 and MD-2 also are localized, appears to
have a correspondingly important function (37).
Toll-like receptors
The discovery of Toll, and hence the TLRs , came about as a consequence of a
forward genetic screen in the Nusslein-Volhard laboratory (10). Nusslein-Volhard and
her group were searching for developmental mutants in Drosophila, and identified a
lesion that later proved to be involved in both early development and insect immunity.
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Drosophila Toll itself is a type I transmembrane protein with an extracellular domain rich
in leucine repeats , and a cytoplasmic domain with an area of high homology to the human
interleukin 1 receptor (38). Flies that carred the Toll mutation proved to have severe
defects in the production of antimicrobial peptides when challenged with either
filamentous fungi or Gram positive bacteria (39). The completion of the Drosophila
genome revealed 8 homologs. Remarkably, the recognition of Gram negative bacteria is
probably through the recognition of Gram negative peptidoglycan by peptidoglycan
recognition protein (PGRP) Lc (40-42), which has no structural similarities to Toll.
Indeed, fly cells have no ability to respond to LPS (43).
One important issue is whether or not Toll (or TLRs) actually bind microbial
products. In fles , Toll is activated indirectly after fungal invasion. The ligand for Toll is
known as spatzle, a peptide that is cleaved from a propeptide as a result of the activation
of a serine protease cascade by fungal elements. During development, proteolytic
cleavage of spatzle by the serine protease Easter leads to proper dorsal-ventral patterning
of the Drosophila embryo (44). In contrast, a different protease named "spatzle-
processing enzyme" is responsible for spatzle cleavage during the Drosophila immune
response (45). While the molecular genetic evidence that spatzle binds Toll has been
strong for many years , actual data demonstrating high affnity binding of purified spatzle
to Toll was not published until recently (46). This is characteristic of the entire
progression of knowledge in the Toll field, where molecular genetics have identified
probable receptors, but biochemical demonstrations of ligand binding have lagged far
behind. Very few TLR ligands have been definitively shown to bind their cognate
receptor. Indeed, the most obvious example of this gap in our knowledge is LPS , where a
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direct demonstration of LPS binding has not been definitively made; leading some to
speculate that a spatzle-like molecule must exist. This is supported indirectly by studies
carried out in the early 1980' s showing that treatment of cells with the serine protease
trsin, enhanced LPS sensitivity while inclusion of the serine protease inhibitor, STI
diminished LPS signaling.
The first TLR to be identified as a putative LPS receptor was TLR2 (47, 48).
Subsequent studies showed that these initial reports were flawed, because the LPS
preparations used appeared to be contaminated with bacterial lipoproteins , which we now
know can activate TLR2 (49). In fact, early studies established that TLR2-deficient
hamsters responded to LPS, and we now know that the primary TLR responsible for
(most) LPS responses is TLR4. The evidence for this conclusion began with the
observation that two strains of LPS hyporesponsive mice had mutations in TLR4 (50).
One of these strains , the C3H/HeJ mouse, had been widely studied for over three
decades. The C3H/HeJ mouse contains a single point mutation in the "BB loop" of the
TIR domain of TLR4: a pr0712his that converted this mutant TLR4 into a dominant
negative gene when coexpressed with a wild-type gene (50). Similar mutations in other
TLRs and TIR-domain containing adapter molecules often result in dominant negative
suppressing activity.
After the initial discovery that a point mutation in TLR4 accounted for the LPS
response defect in C3H/HeJ mice, there was a brief pause in progress on the LPS
receptor. Many groups had the frustrating experience oftransfecting TLR4into HEK293
cells and finding that the cells remained unresponsive to LPS , although there were some
reports that expression of TLR4 in a TLR4-null cell resulted in LPS responses. The
discrepancies observed between labs that had performed nearly identical experiences
were due to the unappreciated role ofMD- , a soluble TLR4 co receptor.
MD-
Several observations helped resolve the initial confusion concerning the
identification of TLR2 as the LPS signal transducer. First, was the discovery that
Chinese hamsters were natural null mutants for TLR2 expression. Yet, cells from
Chinese hamsters respond exquisitely well to LPS (51). Hirschfeld and colleagues
clarified the exact basis of the problem when they found that when LPS was subjected to
a second phenol extraction, which removes trace amounts of bacteriallipopeptides (49),
all of the TLR2 activity, but none of the TLR4 activity, was lost.
Most important in characterizing the central role of TLR4 in LPS signal
transduction was the discovery of MD-2 (52). MD-2 is an 18-25 kDa protein with a
cleavable signal sequence that is both bound to TLR4 in the Golgi and is secreted as 
soluble molecule from MD-2 expressing cells (53 , 54). Miyake and co-workers found
when MD-2 was co transfected into HEK293 cells, it bound to TLR4, and greatly
enhanced the response of TLR4-transfected cells to LPS (52). A forward genetic screen
of CDl4-transfected CHO cells , performed by Golenbock et aI. revealed that MD-2 is
essential for LPS responses. Indeed, they found that MD-2 can be supplied as a soluble
receptor component to TLR4 positive cells (54). It is now believed that earlier reports on
TLR4 responsiveness in HEK cells is attributed to the presence of small quantities of
soluble MD-2 in some lots fetal calf serum but not others.
TLR4/MD-2 initiation of signal transduction
TLR4 does not appear to bind LPS directly (36). But, evidence abounds that MD-
, which is bound to TLR4, binds LPS. Indeed, it has been suggested that MD-2/LPS
complexes , and not LPS , may function like spatzle as a protein ligand for TLR4.
MD- , at least when transfected into cells, is secreted as both a monomeric
protein and a series of polymeric proteins of variable molecular weight. Studies by Re
and Strominger (55), as well as Visintin and Golenbock (36), have demonstrated that
only the monomeric form of MD-2 is biologically important for LPS signaling. There
appear to be two reasons for this: first, only monomeric MD-2 binds to LPS. Secondly,
only the monomeric form ofMD-2 binds to TLR4.
The exact locations of the LPS binding site on MD- , as well as the nature of the
MD-2 binding site on TLR4, are not known. It has been hypothesized that the contact
point of MD-2 with TLR4 involves amino acids 95 and 125 on MD- , based upon the
observation that a C95Y mutant of MD-2 failed to bind surface MD-2 (36), and the
observation that a CI05 mutant similarly lacked biological activity (56). The C95Y
mutant clearly failed to immunoprecipitate with TLR4. Furthermore, a region of MD-
that shares some sequence homology with bactericidal permeability increasing protein
(BPI), another LPS binding protein, has been identified. Two amino acids in particular
lysines 128 and 132, have been proposed as cationic interaction sites for the 1 and 4'
phosphates of lipid A. A model describing the events leading to LPS recognition by the
TLR4/MD2 complex is shown in Figure 1.4.
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TLR4 Signal Transduction and the TIR domain containing adapter molecules
Once LPS binds to TLR4/MD- , the mechanism whereby the receptor becomes
activated is unclear. Studies suggest that the aggregation of TLR4, either artificially
using mAbs , or as a result of LPS binding, is suffcient to activate signal transduction
(57). The next step in the signaling process involves the recruitment of TIR domain
containing adapter molecules to the cytoplasmic face of the TLR4 cluster via homophilic
interactions with the TIR domain ofTLR4.
As of2002 , when I began my Ph.D. studies , three TIR domain containing adapter
molecules were known to mediate TLR4 signaling. All three share significant amino-acid
sequence similarity within their TIR domains, including (in order of their discovery):
myeloid differentiation factor 88 (MyD88) (15); MyD88 adapter-like (Mal) (16), also
called TIR domain-containing adapter protein (TIRP) (17); TIR domain-containing
adapter inducing interferon (IFN)- (TRIF) (18), also called TIR domain-containing
adapter molecule-l (TICAM- l) (19). fourth TIR domain-containing protein called
SARM (for "Sterile alpha and HEAT/Aradilo motif protein ), which encodes an
orthologue of Drosophila and C. elegans proteins , also exists in mammals. Similar to the
other adapters , SARM contains a TIR domain in its C-terminus; however, its inability to
activate either the NF-KB or IRF3 pathway (see below) makes its role in TLR signaling
unclear at present (23). Other TLRs also recruit some of these same adapter molecules
but TLR4 is unique in that it requires at least three to develop a comprehensive immune
response. A schematic representation of these adapters is shown in Figure 1.5.
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MyD88
MyD88 was originally isolated as a gene induced during IL-6-stimulated
differentiation of Ml myeloleukemic cells into macrophages (58). It was subsequently
cloned as a TIR and death domain (DD)-containing protein recruited to the C-terminal
TIR domain of the IL- l receptor (IL- IR) (15). MyD88 recruits the serine/threonine
kinase, IL- IR-associated kinase- l (IRAK1) via its N-terminal DD (15) and forms both
homodimers as well as heterodimers with other TIR domain containing adapters. In
addition to its ability to interact with the IL- , MyD88 is also recruited to the TIR
domain of other TLR family members, with the exception of TLR3. MyD88 , therefore
functions as a shared component oflLIR1TLR signaling.
The importance of MyD88 in LPS-mediated TLR4 signaling in vivo was first
demonstrated when MyD88-deficient mice were generated by Shizuo Akira and
colleagues (59). MyD88-deficient mice were refractory to LPS- induced death and failed
to secrete cytokines such as IL- 6 and TNF-a in vivo or in vitro in LPS-stimulated
macrophage cultures (59). Intriguingly, NF-KB translocation and phosphorylation of
mitogen-activated protein kinases (MAPK), although slightly delayed by 10 minutes
were not eliminated, indicating the existence of a MyD88-independent pathway for TLR4
signaling (59). Other TLRs (60) (except TLR3) and IL- IR family members require
MyD88 for signaling. TLR4 is unique, however, in its ability to activate both MyD88-
dependent and MyD88-independent responses.
Two key features of MyD88-independent signaling is the induction of a DC
maturation pathway and the induction of the tye 1 interferon (IFN-f3) and IFN-regulated
genes (61 , 62). There is some evidence to suggest that the DC maturation pathway 
dependent on IFN production (63). There is considerable interest in understanding how
IFN is regulated. The transcription enhancer of the IFN-B gene is known to bind NF-
interferon regulatory factor (IRF) 3 , and ATF-2-c-Jun. Whereas all TLRs activate NF-
and ATF2-c-Jun, not all TLRs induce IFN-B because not all TLRs induce IRF3
activation. TLR3 and TLR4 activate IRF3 via the MyD88-independent pathway and, as
such, appear to have diverged evolutionarily from other TLRs to activate gene expression
programs and trigger antiviral responses by a mechanism involving the coordinate
activation ofNF-KB and IRF3. A recent micro array study performed by Bjorkbacka et al.
has revealed that 76% of 913 genes induced in LPS-treated wild-type macrophages are
stil induced in LPS-treated MyD88 KO macrophages (64) suggesting that MyD88-
independent signaling accounts for the majority of the LPS response.
Mal/TlRAP
MyD88 adaptor-like protein (Mal) (16); also called TIRAP (17), is a related TIR
domain-containing protein, which was discovered based on its ability to mediate TLR4
but not IL- IR signaling. Mal possesses a C-terminal TIR domain, but lacks the N-
terminal DD present in MyD88. -Like MyD88 , Mal is capable of both homo- as well as
hetero-dimerization with other adapter molecules, at least by coimmunoprecipitation
assays, presumably via TIR-TIR interactions. LPS-induced cytokine production is
severely impaired in Mal-deficient macrophages (65 , 66); however, responses to flagellin
(TLR5), the immune response modifier resiquimod (R-848) (TLR7), CpG DNA (TLR9),
IL- , and IL- 18 were normal in these macrophages. Unexpectedly, TLR2 signaling in
Mal-deficient splenocytes and macrophages was also impaired. Mal-deficient
macrophages also showed delayed NF -KB translocation and MAPK phosphorylatio
induced by LPS , whereas TLR2-mediated NF-KB translocation was essentially eliminated
(65, 66).
Mal had also been implicated in LPS-induced IFN- induction in vitro and, as
such , represented a likely candidate responsible for the regulation of MyD88-independent
signaling (61). However, activation of IR3 and induction of IFN- and IFN-stimulated
genes is intact in Mal-deficient cells (65). These observations prompted database searches
for additional TIR domain containing adapter molecules, which might regulate MyD88-
independent signaling.
TRlF/TICAM-
The third TIR-containing adapter, called TRIF or TICAM- l was discovered based
on its contribution to TLR3 signaling (18 , 19). TRIF is a much larger protein than either
MyD88 or Mal (712 amino acids vs. 296 and 235 , respectively) and possesses the
conserved proline (434p) found in the BB loop of other TIR domains (except that of TLR3
which has an alanine). Overexpression of TRIF results in NF-KB activation; however
only overexpressed TRIF , but neither MyD88 or Mal, leads to strong expression of IRF3-
dependent reporters such as the IFN- gene reporter (18 , 19).
The role of TRIF in TLR signaling was confirmed using siRNA silencing
technology (19, 20) and either TRIF-deficient (60) or chemically mutagenized (lps2)
mice (67). TRIF-deficient macrophages are extremely deficient in their capacity to induce
IFN-(3, RANTES, IP-I0 and MCP- l gene expression, and their B cells can neither
proliferate nor increase the expression of activation markers in response to TLR3
activation (60). Deficiency ofTRIF also affects LPS-induced cytokine gene expression in
macrophage cultures, but does not alter cytokine expression induced by peptidoglycan
(via TLR2), R-848 (via TLR7), or CpG DNA (via TLR9) (60). In addition, TRIF-
deficient fibroblasts and macrophages failed to activate IRF3 in response to either TLR3
or TLR4 activation. NF-KB is activated by LPS in these cells, but not by poly I:C
indicating roles for both MyD88 and TRIF in NF-KB activation through TLR4. This is
supported by the observation that LPS fails to induce NF-KB activation in fibroblasts
from TRIF/MyD88 double-deficient mice (60).
Lps2 chemically induced mutation that led LPS-challenged
hyporesponsiveness in mice was identified as a single base-pair deletion in TRIF that is
predicted to replace the C-terminal twenty-four amino acids with an unrelated eleven
amino acid sequence (67). Nonetheless, the mutated TRIF gene stil has the potential to
encode a protein that contains a TIR domain and an N-terminal region. The Lps2 mutant
mice exhibited a similar phenotype to that seen with TRIF-deficient mice (60).
Experiments in mice that harbor both the MyD88-deficiency and the Lps2 mutation
revealed that both adapters normally contribute to LPS-induced TNF-a secretion. It
remains unclear why TLR4-dependent signaling utilizes both MyD88-dependent as well
as MyD88-independent pathways to induce inflammatory cytokines. These findings
might indicate that the MyD88-independent/TRIF-dependent pathway regulates the
expression of a factor or factors required for inflammatory gene expression.
5 Type 1 Interferon
PRRs have the important role of detecting and alarming the host to the presence
of a pathogen. Upon ligand recognition of P AMPs PRRs activate complex signal
transduction pathways that lead to the activation of host transcription factors and the
induction of immune related genes. Some of the most prominent transcription factors
include NF- , ATF-2/c-Jun (AP- l), and interferon regulatory factors (IRFs). The
transduction pathways of NF-KB and AP- l activation have been well characterized.
However the activation pathway of IRF family members was unclear.
The induction of type Interferon
Distinct sets of genes that are induced upon infection are the type 1 interferons
(IFN-a and IFN-(3) and interferon inducible genes (ISGs). The induction of type 1 IFN
and ISGs are instrumental in defending against viral challenge. Incidentally, defending
against bacterial infection may also require induction of these genes as LPS and several
bacterial pathogens and bacterial DNA have also been shown to induce type 1 IFN in
certain cell types (62). Type 1 IFNs act in an autocrine and paracrine manner by signaling
through the IFN-a/f3 receptor. Key signaling components of the IFN-a/f3 receptor are the
signal tranducers and activators of transcription (STATs). Phosporylation of STATs by
Janus kinases (JAKs) leads to their dimerization and nuclear translocation (reviewed in
(68)). As a result, several hundred genes classified as ISGs are induced. Many of these
genes directly help combat viral gene expression and replication (e. , the double
stranded RNA-dependent protein kinase, PKR). In addition, ISGs can also lead to other
effects in the host that help control cell growth and/or apoptosis. IFN-f3 is a good example
of a gene induced upon infection. Its transcriptional control reqUIres the specific
activation ofIRF3 along with NF-KB and AP- l transcription factors.
IRF3 activation
Virus-induced IRF3 activation has been well documented. In addition, IRF3
activation can be achieved by stimulating cells with the synthetic TLR3 agonist poly
(I:C) or the TLR4 agonist LPS. The molecular mechanisms regulating IRF3 activation
were unclear until recently. IR3 is a ubiquitously expressed gene, which normally
resides in the cytoplasm of resting cells. Upon infection with virus, IR3 
phosphorylated at its C-terminus. This phosphorylation is thought to induce
conformational change in IR3 that leads to its homodimerization and/or
heterodimerization with other IRFs resulting in nuclear translocation. In the nucleus IRF3
associates with co-activator proteins CBP and p300 and regulates the transcription of
IFNf3 and ISGs (reviewed in (69)).
A key unidentified component of the IRF3 activation pathway is the identity of
the kinase(s) responsible for phosphorylating IRF3 on its C-terminus. This kinase was
often referred to as the virus-activated kinase or V AK (70). Studies using small molecule
inhibitors and site directed mutagenesis of serine/threonine resiudes suggested that V 
was a serine/threonine kinase and the targets were in the C-terminal cluster comprising
serines 385 , 386 , 396 , 398, 402 , 405 and threonine 404 (71 , 72). Defining the identity of
V AK was a major goal of the IFN field. Whether V AK is also required for non-viral
stimuli acting on IR3 is also unclear.
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1.6 Thesis Objectives
The following studies were aimed at addressing the molecular gaps in our
understanding of TLR4 signal transduction, the activation of IRF3 and the induction of
type 1 IFN and ISGs. In this regard, we were interested in defining these events in the
context of LPS , but also in the broader sense of anti-viral immunity. Although much
insight into how the innate immune system begins to function and interact with the
adaptive immune system has been gained, many gaps stil exist. The identification of the
novel components in the signaling pathways discovered in the research that follows may
lead to further breakthroughs and possibly into the development of new treatments for
infectious disease.
Figure 1.1 Complement Pathways. Classic, lectin, and alternative complement
pathways. Copyright (9 Lippincott Wiliams & Wilkins.
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Figure 1.2 Toll-like Receptors. The mammalian Toll-like receptors are type 1
transmembrane proteins with extracellular leucine rich repeats. The intracellular TIR
domain of TLRs is also present in the ILIR. Ilustrated are 9 TLRs and the ILIR with a
representation of their known ligands (Not shown: TLRI0).
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Figure 1.3 The cellular localization of TLRs. Ilustrated is the localization of TLRs
within the cell. Surface TLRs (1, 2 , 4, 5 , and 6) recognize microbial components of the
outersurface of pathogens or components that are often shed from pathogens. TLRs (3 , 7
and 9) are localized to the endoplasmic reticulum and traffc to the endosomal
compartments. Here they encounter ligands (nucleic acids) from digested pathogens (73).
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Figure 1.4 Mediators of endotoxin recognition. The recognition of endotoxin occurs
via a series of proteins that bind LPS and synergistically act to enhance the response to
infection. See text for detail.
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Figure 1.5 TIR-domain containing adapter molecules as of 2002. schematic
representatio of MyD88 , Mal/TIRP , TRIF/TICAM1 , and SARM is shown. The
position of the TIR domain in all proteins is indicated. MyD88 contains a death domain
in its N-terminus , Mal contains a PEST domain and SARM contains two SAM domains.
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CHAPTER II:
IKKE and TBKI are essential components of the IRF3 signaling pathway.
Abstract
The transcription factors IRF3 and NF-KB are required for the expression of many
innate immune response genes. Viral infection, the recognition of dsRNA by TLR3 , or
LPS recognition by TLR4 results in the coordinate activation of IR3 and NF-KB.
Activation of IRF3 requires signal-dependent phosphorylation , but little is known about
the signaling pathway or kinases involved. Here we report that the non-canonical IKB
kinase homologues, IKB kinase epsilon (IKE) and TANK-binding kinase- l (TBK- I),
which were previously implicated in NF-KB activation, are also essential components of
the IR3 signaling pathway. In addition, we have also examined the expression of IRF3-
dependent genes in mouse embryonic fibroblasts (MEF' s) derived from TBKr mice.
We find that TBKI is required for IRF3 activation and nuclear localization in primary
mouse embryonic fibroblasts (MEFs). Moreover TBKI- MEFs show marked defects in
IFN-a/f3, IP- , and RANTES gene expression following infection with either Sendai or
Newcastle Disease viruses, or engagement of the TLRs 3 and 4 by dsRNA and LPS
respectively. Finally, the TIR domain-containing adapter molecule
, TRIF, fails to
activate IR3-dependent genes in TBKI- MEFs. Thus, IKE and TBKI playa pivotal
role in coordinating IR3 activation in the innate immune response.
Introduction
IRF3 is required for IFN - and RANTES expression in response to viral infection
(74-76). In unstimulated cells , IR3 is present in the cytoplasm. Viral infection results in
the phosphorylation of IRF3 leading to its dimerization and interaction with the co-
activators CBP-p300 (74). The IRF3 complex then translocates to the nucleus where it
activates promoters containing IRF3 binding sites. In spite of considerable effort, neither
the components of the signaling pathway nor the kinases involved in the phosphorylation
ofIR3 have been identified (69 , 77-79).
Two distinct pathways for the activation of the innate immune response by viral
infection have been identified. In one pathway, viral nucleocapsid proteins trigger
signaling cascades leading to IR3 activation (80). The receptor and signaling
components for this IR3 signaling pathway remain to be identified (81). In the second
pathway, NF-KB activation by virus infection or dsRNA requires the IKB kinase-f3
(IKf3) component of the IKKaf3y complex (82). The IKKa y complex contains two
closely related kinases (IKKa and IK(3) and a third structual subunit, IKKy (83). The
dsRNA activated protein kinase (PKR) may also be involved but its in vivo significance
is controversial (16 , 82 , 84).
The Toll-like receptor, TLR3 , recognizes dsRNA generated during viral infection
(85). Signal transduction through TLRs requires the conserved TIR domain, which
facilitates recruitment of the TIR domain-containing adapter molecule, MyD88 (86). The
association of MyD88 with receptor TIR domains results in recruitment of the IRAK-
and -4 kinases (87), upstream components of the signaling pathway, which leads to
activation of the canonical IKKapy complex
, and ultimately NF-KB activation (83).
TLR3 also activates IRF3 (88).
Recently, TLR3 (85 , 88) and TLR4 (61 , 62) were shown to signal independently
of MyD88 to induce IFN-p. As presented in the introduction 
Mal/TIRP (16, 17) also
plays an essential role in the NF-KB activation pathway in response to lipopolysaccharid
(LPS), but is not required for IFN-
induction (89). A third adapter protein
TRIF/TICAM- l mediates TLR3-dependent IRF3 and NF-
KB activation(18, 90). The
signaling components regulating IRF3 and NF-KB activation downstream ofTLR3-
TRIF
have yet to be identified (91).
In contrast, the canonical IKKapy complex is required for TLR3-
TRIF mediated
NF-KB activation (KA.F. and D. , unpublished). Activated lKapy 
phosphorylates
serines 32 and 36 of the NF-KB inhibitor protein IKBa
, leading to its polyubiquitinati
and degradation by the proteosome (83). This , in turn, leads to the translocation ofNF-
to the nucleus where it activates the transcription of target genes (92).
Two related IKB kinase homologues , IKKB (93) (also called IKKi 
(94)) and
TBKI (also called NAK, for NF-KB-activating kinase (95) or T2K
, for TRAF-
associated kinase (96)) have also been implicated in NF-KB activation. NF-
KB-dependent
genes are not expressed in embryonic fibroblasts from TBK1-
deficient mice , which die as
a consequence of apoptotic liver degeneration (96). The target of TBKI in the NF-
activation pathway is unknown (97), but does not appear to be IKBa (96). A potential
target of IKKB and TBKI is the RelA protein, also called p65. 
Both kinases can
phosphorylate p65 on serine 536 (S. M. and T.M. , unpublished), an event
, which is
essential for p65 transactivation (98). Mice with a targeted disruption of 
IKKs have yet to
be reported.
In an effort to identify potential downstream targets of IKE and TBK1 , we
conducted a detailed analysis of the role played by these kinases in regulating 
IFN-fJ and
RANTES gene expression. We found that in addition to their role in the NF-KB pathway,
these kinases are essential for the activation of the IR3 pathway following viral
infection, TLR3 stimulation by dsRNA, and TLR4 stimulation by LPS.
Materials and Methods
Reagents. Promoter elements from - 110 IFN CAT (99), PRD(III-I)3-CAT (99) and
PRD(II)z-CAT (100) were amplified by PCR and cloned into pLuc-MCS (Stratagene) to
generate pLuc-IFNfJ pLuc-PRD(III-I)3 and pLuc-(PRDII)z. PRD(IV)6-CAT is 
described (100). The ISG54 1SRE was from Stratagene. The RANTES-luciferase , IRF3-
5D and IRF3-GFP were from John Hiscott, (Montreal, Canada). The NF- KB-luc and the
IKB super repressor (IKB SR) were as described (16). The ELAM-luc was from D.
Golenbock (Worcester, MA). The IP-1O reporter construct was from A. Luster
(Massachusetts General Hospital Boston, MA). pCDNA3-Flag- IKKB IKKf3,
IKE(K38A) and pCDNA3-T7-IKK were as described (93). pCDNA3-Flag-TBKI and
TBK1(K38A) were from Makoto Nakanishi (Nagoya, Japan). pCDNA3-T7-TBKI was
generated from pCDNA3-Flag-TBKl. pEF-Bos-Flag murine TRIF was generated by
PCR cloning from a RA W264.7 cDNA library. HA-IR3 N was from T. Fujita (Tokyo
Japan). GaI4-IRF3 and Ga14-IR3 A7 were as described (99 , 101). IRF3 N was from
Takashi Fujita (Tokyo, Japan). pEF-Bos-Flag Mal (TIRAP) and TRIF (TICAM- l) were
generated by PCR cloning from a human PBMC cDNA library and pEF-Bos-TRIF-TIR
(aa387-566) was derived from full length TRIF by PCR cloning (K.A.F. and D.T. G.
Cell lines. HEK293 stable cell lines expressing fluorescent full length TLR3 or IRF3-GFP
were engineered by calcium phosphate transfection, selection of bulk populations of cells
by selection in the neomycin analog G418 (1mg of total drug/ml) and positive selection
fluorescence-activated cell sorting Dickinson(BD Vantage Becton
Immunocytometry) as described (57). Mouse embryonic fibroblasts (MEFs) from wild-
tye and TBK1-deficient mice were provided by Wen-Chen Yeh (University of Toronto
Toronto) as described (96).
Transfection assays. Cells (1.5 x 10 cells per well) were seeded into 96-well plates and
transfected on the following day with 40 ng of luciferase reporter genes using FuGENE6
(Roche). The Renila- luciferase reporter gene (Promega) (40 ng) was cotransfected for
normalization. In other experiments , MEFs from TBKI +/+ and -/- mice (7500 cells/well)
were plated in 24-well plates and transfected 24 h later with 0.25!Jg of reporter genes as
indicated using FuGENE6 (Roche, Indianapolis). 0. !Jg of murne TRIF was also
cotransfected with reporter genes where indicated. 24h after transfection, some cells were
infected with NDV or SV (200 HAU), stimulated with LPS (100 ng/ml) or poly IC (50
!Jg/ml) as indicated. In all cases , celllysates were prepared and reporter gene activity
measured using a Dual Luciferase Assay System (Promega). Data are expressed as mean
relative stimulation:: S.D. for a representative experiment from a minimum of 3 separate
experiments , each performed in triplicate. Whole celllysates were also subjected to SDS-
PAGE and immunoblotted to evaluate expression amounts of various epitope-tagged
constructs (data not shown).
RNA interference. Oligonucleotides were cloned into pSuper (kindly provided by R.
Agami) to express the sihIKKE, sihTBK1 , sihIKK hairpins downstream of the human
HI RNA promoter as described (102). The following sequences were targeted: For
sihTBK1 , GACAGAAGTTGTGA TCACA; for sihIKKE GAGCT A TCTCACCAGCTCC;
for sihIKKf3, GTACAGCGAGCAACCGAG; or for sihp53 (102). For reporter assays
o ;.
HEK293 or 293T cells (6 x cells/well) in 96-well plates were transfected with the
appropriate reporters and siRNA targeting vectors or pSUPER empty vector alone (EV)
as indicated using FuGENE6 (Roche). 72 h following transfection, cells were infected
with Sendi Virus (293T) or stimulated with dsRNA (50 
g/ml poly Ie) as indicated for
16 h before luciferase activity was measured. To determine effciency of gene silencing,
whole celllysates from siRNA transfected 293T cells (12 , well plates , 4 x 10 cells/well)
were subjected to immunoprecipitation and western blotting for TBKI (anti-TBKI IMG-
139, Imgenex) and western blotting for IKK (anti- , IMG- 159, Imgenex). Cell
lysates from Flag-IKs transfected cells were subjected to western blotting for IKE
using monoclonal anti-Flag (M2 , Sigma).
RANTES ELISA. Cell supernatants were harvested from 
IKB TBK1 , IKf3 transfected
or virus-infected 293T cells or dsRNA treated TLR3-expressing HEK293 cells following
siRNA targeting as indicated. Cell supernatants were analyzed for RANTES according to
the manufacturer s recommendations (R&D Systems).
Immunofluorescence and confocal microscopy. A HEK293-IRF3-GFP stable cell line
was transiently transfected with Flag-tagged constructs as indicated. 48 h after
transfection cells were fixed, permeabilized and stained with Cy3-conjugated anti-Flag
antibody (clone M2 , Sigma-Aldrich). DRAQ5 was added to counter stain nuclei. MEFs
from TBKI 
+1+ 
and TBKI- mice were transiently transfected with an expression vector for
IRF3-GFP as indicated. 24 h after transfection cells were infected with SV for 6 hand
imaged. All cells were imaged by confocal microscopy using a Leica TCS SP2 AOBS
microscope.
Co- immunoprecipitation. IRF3-GFP-expressing HEK293 or 293T cells in 10 cm plates
were transiently transfected using the FuGENE6 method with 4 Ilg of the indicated
plasmids. Cells were lysed in 800 III of lysis buffer (50mM Hepes, pH 7. , 100 mM
NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP40 , and protease inhibitors), 24 h after
transfection. Lysates were precleared with protein A sepharose for 1 h. Polyclonal anti-
GFP antibody (Molecular Probes) or anti-Flag (M2 , Sigma) was incubated with the cell
lysates in Protein A sepharose overnight. The immune complexes were precipitated and
washed thoroughly. The protein was eluted by adding sample buffer and was
subsequently run on a 10% SDS-PAGE gel and visualised by immunoblotting for Flag-
or T7- tagged kinases using monoclonal anti-Flag (M2 , Sigma) or monoclonal anti-
(T7-Tag, Novagen).
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Results
Ilrlr8 and TBlr1 induce IFN P and RAJVTES
To investigate the functions of IKE and TBK1 , we examined their effects on the
regulation of innate immune response genes. In particular, we found that the 
IFN-fJ and
RANTES reporter genes were strongly activated by transfection of HEK293 cells with
either IKK€ or TBK1 expression vectors whereas neither gene was activated by
transfection of cells with an expression vector for 
IKKfJ (Fig. 2. 1a and 2. 1 b). In addition
both kinases induced endogenous RANTES secretion, but transfection of 
IKKfJ had little
effect (Fig 2. 1c).
A common feature of the 
IFN-fJ and RANTES genes is that multiple regulatory
elements are required for their activation in response to virus infection. For example
, the
transcription enhancer of the 
IFN-fJ promoter contains four positive regulatory domains
(PRDI-IV), that act cooperatively to activate 
IFN-fJ gene expression in response to virus
infection (103). The transcription factors that bind to these elements include NF -KB,
which binds to PRDII; IRF3 , which binds to adjacent PRDIII and PRDI sites, collectively
referred to as PRDIII- , and the heterodimeric transcription factor ATF-
2-c-Jun, which
binds to PRDIV.
To identify the targets of IKKE and TBKI in the IFN-fJ enhancer, we tested the
ability of these kinases to activate transcription from individual IFN-fJ regulatory
elements. Each of these promoter elements , when present in multiple copies
, can be
activated by virus infection (99, 104). As expected from the previously demonstrated
ability oflKKE and TBKI to activate NF-KB (92 , 97), all three kinases (IKKE, TBKI and
IKK ) activated a reporter gene containing multiple copies of PRDII (Fig. 2.
1d).
Remarkably, a reporter gene containing multiple copies of PRDIII-I was activated by
IKE and TBK1 , but not by IKK (Fig 2. 1e). Consistent with these observations , another
IRF3 dependent promoter element, the ISRE (for Interferon Stimulated Regulatory
Element) of the ISG-54 gene , was activated by IKKE and TBKI expression, but not by
IKK (Fig. 2. 1 f). We were unable to detect significant PRDIV reporter activation by any
of the IKs (data not shown).
Together, these results indicate that all three kinases (IKK , IKKE and TBK1)
activate NF- , while only IKE and TBK1 , but not , activate IR3.
lKKe and TBlr1 activate lRF3
The observation that PRDIII-I and ISRE-containing promoters can be activated by
IKE or TBKI suggests that these IKB kinase homologues can directly, or indirectly
activate IRF3. To test this possibility, we employed an in vivo 
assay for IRF3 activation
which utilizes a hybrid protein consisting of the yeast Gal4JNA 
binding domain (DBD)
fused to IRF3 lacking its own DNA binding domain (103). Reporter gene expression
from the Gal41pstream activation sequence in this assay requires IR3 activation (99).
The Ga14 reporter gene is activated by virus infection in the presence of the wild-type
Ga14- IR3 fusion protein, but not in the presence of a fusion protein in which the
serine/threonine residues critical for IRF3 activation have been substituted by alanine
(GaI4-IRF3-A7) (Fig. 2.2a) (71 , 72).
The wild-type fusion protein was also activated by transfection with IKKe 
TBK1 but not with IKKP, and this effect was not observed with the mutant Ga14- IRF3-
A 7 protein (Fig. 2.2a). In addition, a dominant negative mutant of IRF3 (that lacks the
DNA binding domain) (99), suppressed the induction of IFN- or the ISRE reporter
genes by IKE or TBKI overexpression (Fig. 2. 2b). Transfection of the IkB a dominant
negative ("IKB super repressor" (IkB SR), IkaS32/36A), which blocks NF-KB activation
(83), had a similar effect on the intact IFN-fJ promoter but had no effect on IKE- 
TBK1-induced ISRE activation (Fig. 2.2b).
As a further test of IKKE and TBK1-dependent IR3 activation, we examined
their effects on the nuclear translocation of IRF3. Transfection of 
IKKE:, TBK1, but not
IKKfJ, induced nuclear translocation of IRF3 in a HEK293 cell line stably expressing an
IRF3-GFP fusion protein (Fig. 2.2c).
We hypothesized that IKE and TBKI could phosphorylate IRF3 directly or may
activate an upstream IRF3 kinase. The former possibility predicts that IKKE and TBKI
interact with IR3 directly, or as part of a complex. In this regard, we found that both
IKKE and TBKI associate with IRF3-GFP in co-immunoprecipitation experiments (Fig.
2.2d). When IRF3-GFP was immunoprecipitated with an anti-GFP antibody and
immunoblotted for Flag-tagged IKKE, TBK1 , or IKK , IKKE and TBK1 , but not IKK
were detected. When HEK293 cells, which lack GFP-IR3 , were immunoprecipitated
with anti-GFP antibody, neither IKKE nor TBKI were detected (data not shown). These
observations are consistent with, but do not prove that, IKKE and TBKI directly
phosphorylate IRF3.
IlrlrlJ and TBlr1 siRNA block IRF3 activation
We carried out siRNA knockdown experiments to determine whether IKKE or
TBKI is required for the activation of a PRDIII-I reporter following virus infection.
Iii
Small interfering RNA (siRNA) targeting of 
IKKe, TBK1, or IKKfJ decreased the amount
of the corresponding protein (Fig. 2.3a). Reduction in either IKKE or TBKI protein
resulted in a significant decrease in virus induction of the PRDIII-I reporter (Fig. 2.3b). A
smaller effect was observed with siRNA targeting of 
IKKfJ or the negative control p53.
When the intact IFN-fJ promoter was tested, the effect of siRNA targeting of IKKfJ 
was
comparable to that of IKK& and TBK1 (data not shown). Taken together, these data
strongly support the conclusion that both IKE and TBKI are required for IR3
activation in response to viral infection, attempts to order IKKE and TBKI in the IR3
signaling pathway with kinase inactive mutants and siRNA targeting vectors were
inconclusive. Finally, endogenous RANTES expression was also reduced in cells targeted
by IKK& and TBK1 siRNA , but not by IKKp siRNA (Fig. 2.3c).
As mentioned above , the IFN-fJ gene is a target of the TLR3 signaling pathway
following treatment of cells with dsRNA (105). Indeed, the IFN-f3 NF- and the ISRE
reporters were activated by dsRNA in a HEK293 cell line stably expressing TLR3 (Fig.
2.4a). Similarly, the RANTES promoter was also activated by dsRNA (data not shown).
Finally, dsRNA activated the Gal4 reporter gene in the presence of the wild-type Ga14-
IRF3 fusion protein (Fig. 2.4b), but not the GaI4- IRF3-A7 hybrid protein (data not
shown) (71 , 72). Therefore, we conclude that IR3 plays an essential role in the
activation of these genes in response to TLR3 stimulation.
We therefore examined the role ofIKKE and TBKI in TLR3-dependent signaling.
TLR3 induction of the ISRE reporter following dsRNA stimulation was significantly
inhibited when endogenous IKK& and TBK1 
but not IKKfJ or p53 were targeted by siRNA
(Fig. 2.4c). siRNA targeting of IKK&, TBK1 and 
IKKfJ also inhibited dsRNA induction of
. .  ... -
the intact IFN-fJ promoter (data not shown). Endogenous RANTES expression was also
reduced in cells targeted by 
IKK&and TBK1 siRNA (Fig. 2Ad).
TRlF induces IRF3 via Ilrlr& and TBlr1
To investigate how signals are transmitted from TLRs to IKKE and TBK1 , we
examined the effect of the TLR adapter proteins , MyD88 , Mal, and TRIF (16- , 88
106) on the activation of IR3-dependent genes. Neither MyD88 nor Mal activated the
IFN-fJ promoter or an ISRE reporter gene, whereas both adapters activated NF-
reporters (Fig. 2.5a). As a positive control we showed that a constitutively active form of
IR3 (IR3- 5D) (79) potently induced IFN-fJ and ISRE reporters , but had no effect on the
NF- KB reporter. Overexpression of TRIF strongly induced IFN-fJ ISRE, and NF-
reporter activity (Fig. 2.5b) as well as the GaI4-IRF3 fusion protein (data not shown). We
conclude that TRIF activates IRF3 and NF-KB , both of which are essential for IFN-p
induction.
To determine the role of IKKE and TBKI in TRIF-dependent signaling, we
examined the effect of kinase inactive mutants ofIKKE and TBKI on TRIF- induced IFN-
fJ ISRE and NF- KB reporter activities. Kinase inactive IKKE (K38A) and TBKI (K38A)
inhibited the induction of the IFN-fJ ISRE, and NF- KB reporters by TRIF (Fig. 2.6a). As
expected, dominant negative IRF3 (IR3 N) inhibited TRIF- induced IFN-fJ and the
ISRE reporters, but had no effect on NF- KB reporter activity. In contrast, dominant
negative IKBa (IKB SR) inhibited TRIF-induced IFN-f3 and NF-KB reporters, while no
effect was observed with the ISRE reporter. siRNA targeting of IKK& and 
TBK1 but not
IKKfJ or p53, significantly reduced TRIF-dependent activation of the ISRE reporter (Fig.
6b).
Moreover, IKKE and TBKI associated with TRIF in co-immunoprecipitation
experiments (Fig. 2.6c). When Flag-tagged TRIF was immunoprecipitated with an anti-
Flag antibody, co-expressed T7 -tagged IKKE and TBK were detected by
immunoblotting with an anti T7 antibody. Furthermore, there was no detectable T7-
tagged IKE or TBKI when only the TRIF TIR domain only was used. These
overexpression experiments must be verified with endogenous proteins when appropriate
antibodies are available. Nonetheless, we conclude that IKKE and TBKI play an essential
role in TRIF -mediated IRF3 activation.
TBlr1 is required for IRF3-dependent gene expression in MEFs.
The role of TBKI in IRF3 activation was investigated by using a previously
reported TBKI knockout mouse (96). Previous studies showed that TBKI deficient mice
die at EI4.5 ofliver degeneration due to massive TNF-a induced apoptosis (96). Based
. on the similarity of this phenotype with that observed with RelA- mice, TBKI was
proposed to play an essential role in the NF-KB pathway (96). We therefore carred out
studies to determine the effect of TBK deficiency on IRF3 activation in mouse embryonic
fibroblasts (MEFs). As shown in Figure 2. , induction of an IFN- reporter gene in
response to infection with SV was completely defective in the TBK1-deficient MEFs.
When Newcastle Disease Virus (NDV), another well-characterized inducer of type I
. interferon expression was examined, IFN - reporter gene expression was also completely
brogated in TBK-deficient cells (Fig. 2.7). We also investigated the role of TBKI 
t:""
signaling via TLR3 and 4, following stimulation with poly IC or LPS , respectively.
Induction of the IFN - reporter genes was significantly reduced in TBKI deficient cells
following stimulation with either poly IC or LPS (Fig. 2.7). Furthermore, induction of
both the RANTES and IP- I0 reporter genes also showed similar defects in TBK1-
deficient cells with all stimuli tested (data not shown). Together, these results show that
type I interferon and related genes require TBKI for their expression.
TBlr1 is essential for IRF3 activation.
The inhibition oflFN PRDIII-I and ISRE in TBK1-deficient mice suggested that
in agreement with our previous observations (107), TBKI mediates its effects via IRF3.
We therefore examined the activation of IR3 in TBK1-deficient cells. Viral infection
leads to the phosphorylation of IRF3 followed by its dimerization, nuclear translocation
and interaction with the co-activators CBP-p300 (74). Embryonic fibroblasts from wild
type and TBK1-deficient mice were transfected with a vector encoding an IR3-GFP
fusion protein and nuclear translocation of IRF3 was examined following virus infection
by confocal microscopy. In uninfected cells , IRF3-GFP was expressed in the cytoplasm
of both wild-tye and TBK1-deficient cells. In both cases, the nucleus was almost
completely free of GFP fusion protein (Fig. 2.8). However, when cells were infected with
SV for 6 h, IRF3-GFP clearly translocated to the nucleus in wild type cells. In contrast
IRF3-GFP remained in the cytoplasm in TBK1-deficient cells and no nuclear translocated
IRF3-GFP could be detected following virus infection (Fig. 2.8).
TBlr1 is essential for IRF3 activation mediated by TRIF.
TRIF has recently been shown to activate IR3 and induce IRF3 target gene
expression such as IFN- , RANTES , and IP- I0 (18 , 88 , 107). Recent studies with TRIF-
deficient mice confirm its essential role in tye I interferon induction following
engagement of TLR3 and 4 by poly I:C and LPS , respectively (60 , 108). Furthermore
TRIF -mutant mice, derived by chemical mutagenesis , are hypersusceptable to murine
cytomegalovirus infection, due to a failure to produce type I interferons (108). Taken
together, these observations suggest that TRIF is an essential shared component of the
pathways by which TLRs and viruses induce type I interferon. While some viruses appear
to signal via specific TLRs (109- 111), the precise relationship between TRIF, individual
TLRs , and all viruses is stil unclear.
We have previously demonstrated using siRNA silencing of IKE or TBKI that
the induction of type I interferon and related genes by TRIF is dependent on these kinases
(107). Furthermore, immunoprecipitation studies suggested that TRIF interacted with
IKE or TBKI and this interaction was abolished by deletion of the N or C-terminal non-
TIR domain portion of the molecule (107). IKKE and TBKI have also been shown to
phosphorylate TRIF (112). Overexpression ofTRIF induces IFN- , IP- , and RANTES
reporter gene expression in HEK293 cells (107). We therefore examined the induction of
IFN- , IP- I0 and RANTES reporter genes in wild-type and TBK1-deficient cells. The
induction of IFN- , IP- I0 and RANTES reporter genes by TRIF was completely
abrogated in TBK1-deficient MEFs, confirming the importance of TBKI in mediating
TRIF signaling to these target genes (Fig. 2.9). In contrast, TRIF-induced ELAM reporter
gene activity was normal in either wild-type or TBK1-deficient cells (Fig. 2. , right).
Discussion
Activation of innate immunity requires the integration of complex networks of
signal transduction pathways, leading to the induction of specific sets of genes in
response to a wide range of infectious microorganisms (113). Specificity is achieved by
the coordinate activation of multiple transcription factors that assemble on enhancers
located upstream from target genes. A well-characterized example of this is the human
IFN-fJ gene which requires IR3 , NF-KB and at least one other transcription factor to be
activated in response to viral infection (103).
An essential component of the NF-KB signaling mechanism is the canonical IKB
kinase complex (IKaf3y) (83), which is activated in response to a vast array of signals.
The upstream activators and the downstream target of this complex are well characterized
(83). By contrast, relatively little is known about the related kinases IKKE and TBKI. In
this study, we confirm earlier observations showing that the expression of either IKE
(94) or TBKI (95 , 114) can activate NF- KB reporters; however, the mechanism by which
these kinases activate NF-KB is unclear. Although IKBa does not appear to be a target of
these kinases , the physiological target in the NF-KB pathway has yet to be identified (93-
, 114).
The studies reported here reveal an unexpected role for IKKE and TBKI in IR3
activation, which is an essential component of the IFN- enhanceosome (103 , 104). IR3
activation by virus, dsRNA, or LPS requires phosphorylation on a cluster of
serine/threonine residues in the C-terminus of IRF3 (between residues 385-405) (78).
Substitution of certain serine/threonine residues within this cluster with phosphomimetic
amino acids results in a constitutively active protein, while substitution of the same
."::.:;;", ,::,/?,.
residues with alanine prevents signal-dependent activation (69, 77-79). A recent study
has shown that substitution of serine 396 with aspartic acid, thus mimicking
phosphorylati , is sufficient to activate IRF3 (115). Moreover, serine 396 was shown to
be phosphorylated in vivo 
in response to viral infection or treatment with dsRNA (115).
However, the importance of additional serine residues within the C-terminal cluster
remains controversial (69 , 77-79). Although overexpressed IKKc: and TBKI interact with
IRF3 , additional studies are required to unequivocally demonstrate the in vitro specificity
and in vivo significance of this observation.
We have shown that TLR3 and TRIF function upstream in the signaling pathway
leading to the activation of IKKE and TBK1 by dsRNA. It is known that IKKc: and TBKI
can promote the interaction between a protein called TANK and IKKy (116). TANK was
identified by virte of its interaction with the tumor necrosis factor (TN F) receptor
associated factor, TRAF. Thus, IKKE-TBKI and IKy may all be recruited to the
intracellular domains of cell surface receptors through TRAFs or other adapter proteins.
Activated IKKc: is present in a high molecular weight complex in Jurkat T-cells (93), and
recent studies have shown that this complex contains IKKa y (S. M. and T.M.
unpublished). Although the functional importance of these multiple protein-protein
interactions has not been established, it is possible that IKE and TBKI function in a
multi-kinase complex recognizing downstream targets.
Although IKKc: and TBKI share significant sequence homology and have
indistinguishable activities , they do not appear to be redundant in our cell culture system.
Depletion of either IKKE or TBK1 by siRNA inhibits IRF3 activation by virus infection
dsRNA treatment, or TRIF overexpression. As shown in studies presented here, IRF3
dependent gene expression is defective in TBK1-defecient MEFs. The relative roles of
these kinases in primary cell types , and their functions in the IR3 signaling pathway wil
require further studies in single- or double-deficient mice.
Based on the data presented here and previous reports implicating IKKE and
TBKI in NF-KB activation, we propose that these non-canoncial IKB kinases playa
pivotal role in coordinating the activities of IR3 and NF-KB , which in turn, synergize to
regulate the expression of certain innate immune response genes.
Figure 2.1 Both IKKE and TBKI induce IFN-f3 and RATES. HEK293 or HEK293T
cells were transfected with 40 ng of the following reporter genes IFN-f3 (a), RANTES (b),
IFN-f3 PRDII (d), IFN-f3 PRDIII-I (e) or ISG- 54 ISRE (Stratagene) (f) and cotransfected
with expression vectors for IKKE, TBKI or IKKf3. Twenty-four hours after transfection
some cells were infected with Sendi Virus (Charles River Laboratories , 200 HAU/ml
16 h), as a positive control. In all experiments , luciferase reporter gene activity was
measured and data normalized for transfection effciency with a 
Renila luciferase. (c)
HEK293T cells were transfected with expression vectors for IKKE, TBK1 , or IKKf3 and
twenty- four hours later supernatants were analyzed for endogenous RANTES by ELISA
(R&D Systems).
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Figure 2.2 IKKE and TBKI activate IRF3. (a) HEK293T cells were transfected with 40
ng of a luciferase reporter gene containing the Gal4upstream activation sequen ce and
cotransfected with 
Gal4 DBD, GaI4-IRF3 or Ga14-IRF3-A7 (IR3 serine/threonine 385
386 , 396 , 398 , 402 , 404, and 405 have been substituted by alanine) and cotransfected
with IKKE, TBKI or IKK as indicated. 24 h after transfection, some cells were infected
with Sendi Virus ( 16 h), as a positive control. (b) HEK293 cells transfected with 40 ng
of the IFN-jJ or an ISG-54 ISRE reporter and cotransfected with 40 ng of IKK&, TBK1 
empty vector in the presence of IRF3iJ or IKB SR as indicated. 24 h following
transfection, celllysates were prepared and luciferase reporter gene activity measured. ( c)
IR3-GFP-expressing HEK293 cells were plated on 35 mm glass-bottom sterile tissue
culture dishes (Mattek Co. , Ashland, MA) and transiently transfected with l g Flag-
tagged IKK&, TBK1 , IKKjJ, and visualized 48 h later by confocal microscopy. (d)
HEK293 1R3-GFP cells in 10 cm plates were transiently transfected with 4 g Flag-
tagged IKE , TBK1 , IKK . 48 h later, lysates were immunoprecipitated with polyclonal
anti-GFP antibodies, and western analysis performed using monoclonal anti-Flag
antibody or anti-GFP as shown. The relatively low amount of TBKI is likely a
consequence of its low level of expression. A Flag-expressing lysate was used as 
positive control for western blotting.
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Figure 2.3 IKKE and TBKI are required for viral activation of PRDIII-
I. (a) siRNA
targeting vectors (100 ng) for 
IKK&, TBK1, IKKfJ or targeting vector alone (EV) were
transfected into HEK293T cells. After 72 h, total celllysates were analyzed by 
Western
blotting for endogenous TBKI (A), IKKf3 (B), or co-transfected Flag-tagged IKKE (50
ng) (C). (b) HEK293T cells were transfected with 40 ng of the PRDIlI- 1FN-fJpromoter
and cotransfected with siRNA targeting vectors as indicated for 72 h before 
infection
with virus. Approximately 16 h later, luciferase reporter gene activity was measured
, (*=
significantly different from virus alone (Students t-test
, p
Ol)). (c) Cell supernatants
were also harvested following siRNA silencing for 72 h and endogenous RANTES
productio measured after virus infection by ELISA, (*= significantly different from
virus alone (Students t-test
, p
05)).
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Figure 2.4 IKKE and TBKI are required for IRF3 activation by dsRNA. (a) TLR3-
expressing HEK293 cells were transfected with an IFN-f3 promoter, an NF- KB reporter
(16) or an ISG- 54 ISRE reporter gene (b) or 40 ng of a luciferase reporter gene
containing the Gal41pstream activation sequence and cotransfected with 20 ng of 
Ga14
DBD or Gal4 IRF3. 24 h after transfection, cells were stimulated with dsRNA (50 /lg/ml
poly I:CJ or left untreated for 8 hand luciferase reporter gene activity was measured. (c)
TLR3-expressing HEK293 cells were transfected with an ISRE reporter and
cotransfected with siRNA targeting vectors as indicated for 72 h. Cells were then
stimulated for 8 h with dsRNA (50 /lg/ml poly I:CJ before luciferase reporter gene
activity was measured, (*= significantly different from dsRNA alone (students t-test
Ol). (d) Cell supernatants were also harvested following siRNA silencing for 72 h
and endogenous RANTES production measured after dsRNA stimulation (50 /lg/ml poly
I:C) by ELISA, (*= significantly different from dsRNA alone (students t-test
, p
05).
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Figure 2.5 TRIF activates IRF3. (a) HEK293 cells were transfected with 40 ng of the
IFN-fJ the ISG-54 ISRE or NF- KB reporter (16) constructs and cotransfected with the
indicated amounts of plasmids encoding MyD88, Mal or constitutively active IRF3
(IRF3- 5D) or (b) TRIP. 24 h after transfection, luciferase reporter gene activity was
measured.
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Figure 2.6 Both IKKE and TBKI are required for activation of IRF3 by TRIF. (a)
TLR3-expressing HEK293 cells were transfected with 40 ng of a plasmid encoding 
TRiF
and 40 ng of the IFN-f3 the ISO- 54 ISRE or NF- KB reporter constructs. The same cells
were cotransfected with dominant negative IRF3 (IR3 N), IKB SR , IKK& (K38A) 
TBKI (K38A) as indicated. Twenty-four hours after transfection, luciferase reporter gene
activity was measured. (b) TLR3-expressing HEK293 cells were transfected with 40 ng
of the ISO- 54 ISRE reporter and cotransfected with siRNA targeting vectors as indicated
for 72 h before a second transfection with 40 ng of a TRIF expression plasmid. Twenty-
four hours later, luciferase reporter gene activity was measured
, (*= 
significantly
different from TRIF only (Students t-test
, p
05)) (c) HEK293T cells in 10 cm plates
were transiently transfected with 4 f.g of Flag-tagged TRIF or TRIF - TIR domain vectors
alone or with T7-tagged IKKE, TBKI or empty vector. Twenty-four hours later, lysates
were immunoprecipitated with anti-Flag and Western analysis performed using
monoclonal anti-T7 or anti-Flag as shown. The relatively low amount ofTBKI is likely a
consequence of its low expression.
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Figure 2.7 Reduced IFNf3 reporter gene activity in the absence of TBK1. MEFs from
TBK1 +1+ (filled bars) and TBKI- (empty bars) mice were transfected with an IFN-
jJluciferase reporter gene. Cells were left untreated (none) or infected with NDV or SV
or stimulated with poly IC or LPS. Lysates were assayed for luciferase activity.
Figure 2.
IFN Luciferase
250 ;
200-
150-
100-
none NDV poly IC
IFN Lucilerase
none
TBK1 +1+
TBK1 -
LPS
Figure 2.8 Deficiency of TBKlleads to defective virus-induced nuclear translocation
and phosphorylation of IRF3. MEFs from TBKI 
+/+ 
and TBK1-/- mice were transfected
with 1.0 Ilg of an IRF3-GFP-fusion protein. Samples were left untreated (none) or
infected with SV (100 HAU) and visualized by confocal microscopy.
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Figure 2.9 TRIF induces IFNf3 and RATES reporter genes by means of TBKI.
MEFs from TBK1 +/+ (filled bars) and TBKI- (empty bars) mice were transfected with
IFN-fJ (Left), RANTES (Center) or ELAM (Right) luciferase reporter genes and
cotransfected with a murine TRIF expression vector or left untreated (none). Lysates
were assayed for luciferase activity.
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CHAPTER III:
LPS/TLR4 signaling to IRF3/7 and NF-KB involves the Toll adapters
TRAM and TRIF
Abstract
TRAM is the fourth TIR domain containing adapter protein to be described that
participates in TLR signaling. Like TRIF, TRAM activates IR3 and NF -KB dependent
signaling pathways. TLR3 and 4 activate these pathways to induce IFN-a/ , RANTES
and IP- I0 expression independently of the adapter protein MyD88. Dominant negative
and siRNA studies performed here demonstrate that TRIF functions downstream of both
the TLR3 (double stranded RNA) and TLR4 (LPS) signaling pathways, while the
function of TRAM is restrcted to the TLR4 pathway. TRAM interacts with TRI
MallTIR, and TLR4 but not with TLR3. These studies suggest that TRIF and TRA
both function in LPS/TLR4 signaling to regulate the MyD88-independent pathway during
the innate immune response to LPS.
Introduction
The TLR family is the essential recognition and signaling component of
mammalian host defense (117- 119). At least ten TLRs have been cloned in mammals
which recognize molecular products derived from all the major classes of pathogens.
(117 - 119). TLR signaling to NF -KB originates from the conserved TIR domain, which
mediates recruitment of the TIR domain-containing adapter molecule, MyD88 (106), a
critical adapter molecule utilized by all TLRs except TLR3 (86)). The recruitment of
MyD88 to proximal TIR domains of activated TLRs allows for the interaction and
activation of IRA-family members (87 , 120), and the subsequent activation of tumor
necrosis factor receptor-associated factor-6 (TRAF- (121)). These events, at a
minimum, result in NF-KB activation via the IKaf3y complex (83).
While most of the TLRs seem to be absolutely dependent on the expression of
MyD88 for all of their functions , TLR3 and TLR4 are unique in their ability to activate
MyD88-independent responses as well (59, 61 , 88, 122). feature of MyD88-
independent signaling is the induction of a dendritic cell maturation pathway, and the
induction of the type I interferon IFN-p (18 , 61 , 62 , 88 , 123). The transcription enhancer
of the IFN-fJ promoter binds NF- , IR3 , and ATF-2-c-Jun. While all TLRs activate
NF-KB and ATF2-c-Jun, not all TLRs induce IFN-p, because not all TLRs activate IR3.
Thus TLR3 and TLR4 appear to have diverged evolutionarily from other TLRs to
activate gene expression programs and trgger anti-viral responses by a mechanism
involving the coordinate activation ofNF-KB and IRF3 (124).
MyD88-adapter-like (Mal) (16), also called TIRAP (17), is a related MyD88-1ike
protein, that was discovered based on its ability to mediate TLR4 signaling. Mal/TIRAP
has been implicated in LPS-induced IFN- induction in vitro (61 , 125). However, studies
with Mal/TIRP gene targeted mice show that Mal/TIR functions in the MyD88-
dependent NF -KB activation pathway following LPS stimulation, as well as engagement
of TLR2 by its ligands (66, 89). A third adapter protein, TRIF (19 , 60), interacts with
TLR3 and mediates the TLR3-dependent induction of IFN- via NF-KB and IR3
activation as presented in Chapter II.
Constitutively expressed IRF3 has been implicated in the induction of IFN-f3 (74
126, 127), RANTES (75, 128), and ISG-54/56 expression (129). IRF3 is activated
following phosphorylation on a cluster of specific C-terminal serine residues (74 , 78 , 79),
facilitating its dimerization and interaction with the co-activators CBP and p300 (71 , 72
, 130). The activated IRF3 complex then translocates to the nucleus where it regulates
the transcription of target genes (75 , 99). IRF7 is a related transcriptional regulator that is
expressed mostly in lymphoid cells and is essential for IFN-a gene expression (131 , 132).
The transcription of IRF7 is induced by IFN and post-translationally activated by
phosphorylation on its C-terminal serine residues , some of which are conserved with
IRF3 (131 , 133). IKE (93 , 94) and TBKI (95 , 96 , 114) are key regulators of the IRF3
and IRF7 activation pathways in cells that have been exposed to some viruses and/or
activated by double stranded RNA via TLR3 (70 , 107). IKE and TBKI are also required
components of the TRIF signaling pathway resulting in IRF3 activation (107).
Studies with IR3-deficient mice have established an essential role for IRF3 in
LPS-induced IFN- gene expression and endotoxin shock (134). However, the molecular
mechanisms regulating the MyD88-independent LPS/TLR4 pathway to IRF3 and NF-
activation are unkown. Here, we have identified a fourth TIR domain containing
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adapter molecule, which we have named TRAM (TRIF-Related Adapter Molecule).
TRA, like all of the TIR-domain containing adapter molecules, activated NF-KB. In
addition, TRA, like TRIF , activated IRF3 and IR7. Unlike any of the other known
TIR domain containing adapters, TRAM appears to be restricted to the LPS activation
(TLR4) pathway while TRIF plays an essential role in both TLR3 and TLR4 pathways
leading to IRF target gene expression. Our findings suggest that TRAM may have
evolved to mediate TLR4 specific signals resulting in a gene expression profile that is not
shared by TLR3.
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Materials and Methods
Reagents. The IR3- , GaI4-IRF3 and Gal4-1uciferase reporter gene were from T.
Fujita (Tokyo , Japan). IKKE-k38a and TBK1-k38a were as described (93 , 107). IRF7
IRF7DN and Ga14-IR7 were from P. Pitha (Baltimore, Maryland). The RANTES-
reporter construct was as described (128). The IP- I0 reporter construct was from A.
Luster (Massachusetts General Hospital, Boston, MA). The NF-KB-luciferase construct
(16), pEF-Bos-Flag Mal and Flag-TRIF were as described (107). The plasmids pEF-Bos-
Flag-TRA, TRAM-CFP, TRIF-CFP and Mal-CFP were generated by PCR cloning
from a human PBMC cDNA library. pEF-Bos-TRAM-TIR (amino acids 63-235), pEF-
Bos-TRAM-C117H, TRAM-P116H and TRIF-P434H were generated using the Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla, CA). Polyclonal antibodies to
IRF3 were from Zymed (San Fransisco, CA) and CBP were from Santa Cruz (Santa
Cruz, CA). pCMV TRIFDNDC and MyD88-deficient mice were gifts from S. Akira
(Osaka, Japan); the MyD88 knockout mice used were backbred onto a C57BL6
background for five generations. LPS derived from Escherichia coli strain 0 I1:B4 was
purchased from Sigma, dissolved in deoxycholate and re-extracted by phenol:chloroform
as described (49). Poly IC was from Amersham Pharmacia (Piscataway, NJ).
Stable cell lines. We engineered clonal stable cell lines by transfecting HEK293 cells
with chimeric fluorescent protein TLR constructs as described (57). A HEK293 cell line
stably expressing both TLR4 and MD-2 was generated by retroviral transduction of
HEK/TLR4 cells with a retrovirus encoding human MD2 (53). HEK/TLR3 , HEK/IR3-
GFP (107) and U373/CD14 cells (135) were generated as described.
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Electrophoretic mobility shif assays. Bone marrow-derived macrophages were cultured
from C57BL/6 mice or age and sex-matched MyD88-1- mice for 8 days in M-CSF (10
ng/ml). Nuclear extracts from 5 x 10 cells were purfied after LPS (10 ng/ml), Malp-2 (1
nM), or Poly IC (50 mg/ml) stimulation for the times indicated. The extracts were
incubated with a specific probe for the ISRE consensus sequence (Promega, Madison
WI), electrophoresed, and visualized by autoradiography (136). Supershift analysis was
performed with antibodies to mouse IR3 , p65 or IgG control.
ELISA. Macrophages (5 x 10 cells per well) were seeded into 96-well plates for 24hrs
prior to stimulation with LPS , poly I:C or medium for 12 h. Cell culture supernatants
were removed and analyzed for the presence of RANTES , IP- , or TNF-a by ELISA
following the manufacturer s instructions (R&D Systems).
Transfection assays. Cells were seeded into 96-well plates at a density of 1.5 x 10 cells
per well and transfected 24 h later with 40 ng of the indicated luciferase reporter genes
using Genejuice (Novagen). The thymidine kinase Renila- luciferase reporter gene
(Promega) (40 ng/well) was co transfected in order that the data could be normalized for
transfection efficiency. Cell lysates were prepared and reporter gene activity was
measured using the Dual Luciferase Assay System (Promega). Data are expressed as the
mean relative stimulation :t S.D. All of the experiments described were performed a
minimum of three occasions and gave similar results.
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Immunofluorescence and confocal microscopy. A HEK293-IR3-GFP stable cell line
was transiently transfected with Flag-tagged constructs as indicated. After allowing two
days for protein expression to occur, the transfected cells were fixed, permeabilized and
stained with Cy3-conjugated anti-Flag antibody (clone M2, Sigma-Aldrich). DRAQ5
was added to counter stain nuclei. Cells were imaged by confocal microscopy using a
Leica TCS SP2 AOBS microscope.
RNA interference. siRNA duplexes targeting the coding region of TRAM and Lamin
A/C Dharmacon (Lafayettefrom CO), TRAM-siRNAwere sequences:
GGAAGAAGTCGTGGATT (product#: A/C:004334-01 TM Lamin
CTGGACTTCCAGAAGAACA. siRNA duplexes targeting the 3' UTR of TRIF were as
described (88). In order to determine the effciency of gene silencing, 293T cells (24 well
plates , 4 x cells/well) were transfected with 0.5 mg of plasmids encoding TRA-
CFP, TRIF-CFP or Mal-CFP expression vectors. These cells were co-transfected with
TRAM or Lamin A/C siRNA duplexes (50nM) using Mirus TransIT(8 TKO and
TransIT-LT1(8 transfection reagents in a combination protocol exactly according to the
manufacturers recommendations (Mirus , Madison, WI). CFP fluorescence was quantified
by flow cytometry (Becton Dickinson, LSR) 24 hours later. For reporter assays
U373/CD14 cells or TLR3-expressing HEK293 cells (4 x 10 cells/well) were transfected
with 0.5mg of the RANTES reporter gene and 0.25mg of a thymidine kinase-renilla
reporter gene and cotransfected with 50 nM of siRNA targeting vectors as described
above in 24-well tissue culture dishes. 36 h following transfection, cells were stimulated
with LPS or dsRNA for 8 h before luciferase activity was measured.
Co- immunoprecipitation. HEK293T cells or TLR-expressing cells (10 cm plates) were
transfected using GeneJuice (Novagen) with 4 mg of the indicated plasmids. Cells were
lysed in Iml of lysis buffer (20mM Tris-HCl , 2mM EDTA, 137mM NaCl , 0.5% TX- I00
Glycerol 10 %, with protease inhibitors) one to two days after transfection. Polyclonal
anti-GFP (Molecular Probes), anti-IRF3 or anti-CBP antibodies were incubated with the
celllysates in Protein A sepharose overnight. The immune complexes were precipitated
and subjected to 4-15% SDS-page and immunoblotted for Flag- or CFPIYFP- tagged
adapters using the anti-Flag mAb M2 (Sigma), or anti-GFP mAb (Clontech), which also
recognizes the spectral variants ofGFP.
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Results
LPS and dsRlA activate IRF3 and IRF7
The promoters of RANTES and IP- , like that of IFN- , contain transcription
factor binding elements for NF-KB and IR3 (75 , 128). The expression ofRANTES and
IP- I0 represent downstream targets of TLR receptors that are entirely independent of
MyD88 expression following stimulation by LPS or dsRNA. Stimulation of mouse bone
marrow-derived macrophages with LPS or dsRNA induced RANTES secretion, an effect
that was observed comparably in bone marrow macrophages deficient in MyD88 (Fig.
1a). This was also true for IP- I0 levels as measured by ELISA (data not shown). In
contrast, TLR2 signaling via lipopeptides absolutely requires MyD88 and did not lead to
RANTES expression. TLR2-mediated production of TNF-a was entirely absent in
MyD88-deficient macrophages (data not shown), in agreement with published reports
(59 , 85 , 137).
We next examined the effect of LPS and dsRNA on IR3 DNA binding activity.
IRF3 DNA binding activity was induced in both wild-type and MyD88-deficient
macrophages following LPS and dsRNA stimulation (Fig. 3. 1b).The presence oflRF3 in
this ISRE DNA binding complex was confirmed by depletion ("gel shift") analysis using
antibodies to IRF3 (Fig. 3. 1 b , lower panel). Stimulation of cells with the TLR2 ligand
Malp- , did not result in IR3 activation. NF-KB was activated in wild-type cells by all
stimuli and in MyD88-deficient macrophages following LPS or dsRNA stimulation (data
not shown).
We next addressed the question of whether the related transcriptional regulator
IRF7 was a target of TLR signaling. We employed an in vivo assay for IRF7 activation
that utilizes a hybrid protein consisting of the yeast Gal4DNA binding domain (DBD)
fused to IRF7 lacking its own DNA binding domain (103). Reporter gene expression
from the Gal4Ipstream activation sequence in this assay requires IR7 activation (99).
IRF3 activation was also measured in this assay using a Ga14 IRF3 fusion protein.
Stimulation of TLR3- or TLR4/MD2-expressing HEK293 cells with dsRNA or LPS
respectively, but not IL- l f3, activated both IRF3 and IRF7 (Fig. 3 . 1 c). IRF7 plays a
critical role in regulating IFN-a expression. Exogenously expressed IR7 increased the
activation of an IFN-a reporter construct when TLR4/MD2- or TLR3-expressing
HEK293 cells were stimulated with LPS or dsRNA, respectively, while a dominant
negative IRF7 mutant inhibited the effect (data not shown). These observations provide
strong evidence that TLR3 and TLR4 activate IRF3 and IRF7 and, as a result, induce
target genes such as RANTES and IFN-a/f3.
Discovery of a fourth TIR domain containing adapter molecule, TRAM
A search of the human genome for additional TIR domain containing adapter
molecules resulted in the identification of a small protein fragment that shares sequence
similarity with other TIR domain containing proteins , most notably with TRIF/TICAM-
A set of overlapping EST sequences were subsequently identified and used to clone the
full-length cDNA of human and mouse TRAM, which shares 75% sequence identity
(Genbank Accession number A Y232653 and A Y268050 , respectively). The TRAM gene
is located on human chromosome 5 (ENSEMBL il: ENSGOOOOOI64226). TRA is a
235 amino acid protein with a C-terminal TIR domain. Figure 3.2a shows a multiple
sequence alignent of human and mouse TRAM with other human and murine adapters
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and TLRs. The crystal structure of the TIR domain of TLR2 has been resolved. The
TIR-domain ' BB-loop ' is an essential part of its strcture, and this portion of the
molecule appears to engage downstream elements such as adapter molecules or other
TLRs (119, 138). Most TIR-domain BB-loop sequences contain a conserved proline
residue in the BB-loop. When this residue is mutated to histidine , the mutant protein is
typically unable to signal, and may even function as a dominant suppressing mutation
(16, 17, 139). Unlike the other known adapter proteins, both human and mouse TRAM
contain a cysteine residue at this position (denoted by a # in Fig. 3.2a). A proline residue
resides directly adjacent to this residue in TRAM , at position 116.
Because of the similarity in the sequence of the TIR domain of TRAM and TRIF
we first compared the effect of TRIF and TRAM on IR3 and IRF7 activation.
Overexpression of TRAM activated both the IRF3 and IRF7 responses (Fig. 3.2b). TRIF
also activated both transcription factors (Fig. 3.2b). As a consequence, TRAM and TRIF
also induced the IFN-B, RANTES , IP- I0 and IFN-alla2 promoters , all of which contain
ISRE elements required for IRF binding (data not shown). These data imply that TRAM
and TRIF also activate NF- , as some of these promoters (IFN-B, RANTES , and IP- I0)
also require NF-KB for full activity (see below).
As a further test of TRAM-and TRIF -dependent IRF3 activation, we examined
their effects on the nuclear translocation of IRF3. Overexpression of TRAM and TRIF in
a stable cell line that expresses a green fluorescent protein chimera of IRF3 resulted in
the nuclear translocation of this IR3-GFP fusion protein (Fig. 3.3a). TRIF has been
shown recently to co-immunoprecipitate with IR3 (18). We were interested in
determining if TRAM might also associate with IRF3. When HEK293 cells were
transfected with Flag-tagged TRA and immunoprecipitated with antibody to
endogenous IRF3 , Flag-tagged TRA could be detected in the immunoprecipitated
complex (Fig 3. , top panel). Immunoprecipitation with an anti-Flag antibody
confirmed this interaction; endogenous and co-transfected IRF3 could be detected in the
immunoprecipitated complexes (Fig 3. , second panel). TRIF also interacted with
endogenous and transfected IRF3 , in agreement with published reports (data not shown).
There were no non-specific associations detected in cells lacking the transfected adapter
constrcts. Although not shown, we also performed similar experiments with IR7.
IR7 also interacted with TRAM and TRIF and vice versa.
Activated IR3 must associate with the co-activators CBP and p300 in order to
enhance target gene expression (71 , 72, 99, 130). When endogenous CBP was
immunoprecipitated from celllysates expressing transfected Flag-tagged TRA, TRAM
could be detected in these immunoprecipitated complexes (Fig 3. , third panel). This
was also tre for transfected TRI (data not shown).
The non-canonical IKB kinases , IKKE (93 , 94) and TBKI (95 , 96 , 114) are key
regulators of the IRF3 activation pathway resulting from viral exposure and activation of
TLR3 or TRIF signaling cascades (70, 107). IKKE has also been implicated in LPS
signaling (140). We next examined the effect of dominant negative mutants of IKKE and
TBKI on TRAM signaling. We used the RANTES reporter gene construct to address
this issue. Cells were co-transfected with TRAM, which activates downstream molecules
as a result of overexpression, and the kinase inactive mutants of IKKE (IKKE-k38a) or
TBKI (TBK1-k38a). Both mutants inhibited TRAM-induced RANTES reporter
activation in a dose-dependent manner, suggesting that these two kinases may also
fuction downstream of TRAM. Taken together, these observations, provide strong
evidence that TRA and TRIF are important components of the IR3 signaling pathway,
and suggest that these adapter proteins form a multi-protein complex with IRF317 , CBP
and the IR3/7 kinases (IKE and TBKl) during signal transduction.
TRAM activates the IRF pathway in the TLR4 but not the TLR3 signaling pathway
We next generated a series of TRA mutants and examined their ability to
activate the RANTES reporter gene. Transfection of HEK293 cells with a plasmid
encoding the TIR domain alone of TRAM (TRAM- TIR) induced the RANTES reporter
although this response was considerably less than that observed with the full length
TRAM cDNA (Fig. 3.4a). TRAM contains a cysteine residue (C117) in the BB-loop
with an adjacent proline residue (P116). Mutation of the proline residue to histidine
(TRAM-PI16H) significantly impaired the RATES inducing activity of TRAM, while
mutation of the cysteine residue at position 117 (TRAM-CI17H) completely abrogated
all activity (Fig. 3.4a). This suggested that either TRAM-CI17H or TRAM-PI16H might
function as a dominant interfering mutant of TRAM activity. The effect of these TRAM
constructs was similar when an IP- lO promoter-based reporter construct was assessed
(data not shown).
We subsequently examined the effect of these TRAM mutants on TLR-mediated
signaling that culminates in RANTES promoter activation or the activation of the
transcription factors IRF3 and IR7. We focused on TLR3 and TLR4 because of their
unique abilities to activate both NF-KB and IR3. Neither the TRAM-TIR domain nor the
TRAM-P116H mutants had any dominant negative inhibitory activity on either TLR-
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dependent IRF3 pathway tested (data not shown). Transfection of HEK/TLR3 cells with
TRAM-C117H had no inhibitory effect on dsRNA-induced RANTES response (Fig.
3Ab). In contrast, LPS-induced activation of the RANTES reporter via TLR4 was
impaired by the TRAM-C117H mutant (Fig 3.4b, left panel). The LPS-dependent
induction of the RANTES reporter gene was considerably less potent than that observed
following TLR3 stimulation. The TRAM-C117H mutant also inhibited the TLR4- , but
not the TLR3-dependent activation of IR3 and IR7 (Fig. 3 Ac). The TRAM -C 117H
mutant also inhibited the TLR4- but not the TLR3-dependent activation of an IP-
reporter construct (data not shown). We also examined the role ofTRIF in the TLR3- and
TLR4-dependent pathways in parallel, by expressing a dominant negative mutant 
TRIF lacking both the N-terminal and C-terminal regions surrounding the TIR domain
(TRIFL\NL\C (18)). As expected, this mutant completely suppressed the TLR3-dependent
response (Fig. 3Ad). The TRIFL\NL\C mutant also inhibited the TLR4-response, although
the effect was less potent than that observed in the TLR3 pathway under identical
experimental conditions (Fig. 3.4d, right panel). Taken together, these observations
suggest that TRIF regulates the TLR3 and TLR4 pathways to 1R-3/7target genes, while
TRAM appears to be TLR4-specific.
TRAM also activates JVF-KB
We subsequently addressed the role of TRAM in the NF-KB activation pathway.
Transfection of HEK293 cells with TRAM resulted in a potent NF-KB activation
response (Fig. 3.5a). The isolated TIR domain of TRAM also induced a robust NF-
response , though this was considerably less than that observed with the full-length gene
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(Fig. 3.5a). Neither the TRAM-PI16H nor the TRA-CI17H mutants induced NF-
activation. Thus , like all ofthe other known adapters , TRAM is also an NF -
KB activator.
The TRA-C117H negative interfering mutant was next tested for its ability to
inhibit TLR-dependent signaling to NF-KB. TLR2- , TLR3- , TLR4/MD2-
, TLR7- and
TLR8-expressing HEK293 cells were transfected individually with an NF-
KB reporter
gene and co-transfected with increasing concentrations of TRAM-CI17H. Following
stimulation with their cognate TLR agonists, luciferase reporter gene 
activity was
measured. NF-KB activation induced by the TLR2 agonist Malp- , the TLR3 agonist
dsRNA, the TLR7 and TLR8 agonist R-848 , IL- lf3, or TNF-a were all unaffected when
cells were co transfected with the suppressing TRAM-C117H mutant (Fig. 3.5b). In
striking contrast to these negative results, the TRAM-C117H mutant inhibited LPS-
induced NF-KB activity in HEKlTLR4/MD2 cells. The TRAM-P116H had no inhibitory
activity on any TLR- pathway to NF- , including the TLR4 pathway, confirming the
importance of the C117 residue for this response (data not shown). These observations
suggest that TRAM regulates NF-KB as well as IR3/7 in the LPS/TLR4 signaling
pathway.
TRIF and TRAM cooperate in the IRF3 activation pathway
We examined the effect of the TRIF C mutant on TRAM-
induced RANTES
promoter activation in order to define the relationship between TRIF
, TRA, and the
TLR4 signaling pathway. The TRIF construct inhibited the TRIF-
induced
RANTES reporter gene response (Fig. 3. , hatched bars). The TRIF C mutant
completely abrogated the TRAM-induced RANTES reporter gene response (Fig. 3.
6a).
The TRAM-C117H mutant also abrogated the induction of the RANTES reporter gene in
response to TRAM overexpression (Fig. 3. , far right), but had no effect on the response
to TRIF overexpression (hatched bars). The observation that a TRIF dominant-negative
construct blocked TRAM activity but not vice versa suggests that TRAM signaling
requires TRIF.
Subsequently, we performed co-immunoprecipitation experiments on cells that
heterologously expressed both of these gene products, as well as the related adapter
molecule Mal/TIRP. These immunoprecipitation studies demonstrated that TRA
interacted with both TRIF and Mal/TIRP (Fig 3. , left panel). TRIF also interacted
with Mal (right panel). Finally, both TRIF and TRA interacted with the Mal-PI25H
(dominant negative) mutant. The stronger interaction of TRIF and TRAM observed with
the Mal-PI25H mutant does not reflect a higher avidity for this interaction, but rather
was a consequence of the higher expression level of the MAL-P125H mutant in whole
celllysates , compared to the expression level of Mal or TRIF (Fig 3.6b. middle panel).
These data may explain a previously unexplained finding, that the Mal/TIR
dominant negative mutant powerfully inhibited LPS-induced signaling to NF-KB (16 , 17)
and IFN- expression (61 , 125), while the Mal/TIRAP knockout mouse both retained the
ability to induce NF-KB (66, 89) and IFN- expression (89). It is likely that the more
profound effect of the dominant negative construct is due to its ability to limit the
function of other adapter molecules involved in LPS signaling such as TRAM and TRIF.
Furthermore, these data suggest that TRIF and TRAM interact with Mal at a site distinct
from the TLR4 interaction site of Mal (17).
Co-immunoprecipitation studies were next performed to determine if TRA
interacts with TLR4. Stable TLR3- or TLR4-expressing cell lines were transiently
transfected with Flag-tagged expression vectors for TRA, TRAM-CI17H and Mal and
co- immunoprecipitation experiments performed. These experiments indicated that
TRAM interacts with TLR4 , but not with TLR3 (Fig. 3.6c), one more indication of the
specificity of TRAM for the TLR4 pathway. The dominant negative mutant TRAM-
C117H, failed to immunoprecipitate with TLR4, suggesting that the C117 residue is
critical for this interaction. Mal also interacted with TLR4 but not TLR3 , providing
additional evidence that Mal has a role in the TLR4, but not the TLR3 , signaling
pathway.
TRlF and TRAM are essential for TLR4 signaling
The data obtained by testing dominant negative constructs and assessing protein:
protein interactions suggest that TRIF and TRA both fuction in the TLR4 signal
transduction pathway. Dominant negative constructs, when highly expressed, have the
potential to bind (e. as seen in Fig 3.6b) and interfere with proteins that might
otherwise not be related to a specific signal transduction pathway. We therefore
performed siRNA silencing experiments as an additional methodology to delineate the
relationship between TRIF and TRAM in the TLR4 and TLR3 signaling pathways.
In order to assess the gene silencing activity of siRNA duplexes we selected, cells
were transiently transfected with a fluorescent chimeric construct of TRAM (TRAM-
CFP) and cotransfected with siRNA duplexes targeting the coding region of TRAM or a
control siRNA, Lamin A/C. These siRNA duplexes can therefore be used to assess the
silencing effect of a fluorescent chimeric constrct of TRAM. This methodology has
been used extensively to assess siRNA efficiency and provides a quantitative assessment
of silencing effciency (102). We found that siRNA duplexes targeting the TRAM
coding region completely ablated the expression of the TRAM-CFP chimeric fusion
protein while lamin AlC siRNA duplexes were without effect (Fig. 3.7a). We also
examined the effect of these TRAM siRNA duplexes on TRIF and Mal expression in
order to insure the specificity of the TRAM siRNA duplexes. This is particularly
important as TRIF and TRAM are most closely related in sequence. TRAM siRNA
duplexes had no effect on chimeric constructs of TRIF or Mal expressed as CFP fusion
proteins (Fig 3.7a).
Having determined that the siRNA duplexes chosen for TRAM effectively and
specifically suppressed TRAM expression, we examined the effect of these siRNA
duplexes on the LPS and dsRNA signaling pathways. Native macrophages and
macrophage cells lines are extraordinarily diffcult to transfect with siRNA. In contrast
U3 73/CD 14 cells resemble central nervous system macrophages , are easily transfectable
and are highly inducible by treatment with LPS. We thus tested the effect of TRAM
siRNA duplexes on the LPS-response in U373-CD14 cells. In comparison, we used
HEK/TLR3 cells to test the effects of TRAM and TRIF in poly I:C stimulated RANTES
expression. The response of each of these cell lines to these TLR ligands is comparable.
TRAM siRNA duplexes inhibited the LPS-dependent induction of the RANTES
reporter gene in U373/CD14 cells , while siRNA targeting of Lamin AlC had no effect
(Fig. 3. , top panel). We also examined the effect of published TRIF siRNA duplexes
which target the 3' untranslated region of TRIF in this response. These TRIF siRNA
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duplexes have been shown to completely silence endogenous TRIF mRA expression
(88). TRIF siRNA duplexes also inhibited the LPS response to RANTES induction (Fig
, top panel). In striking contrast to LPS , when the TLR3-mediated response to
dsRNA was analyzed, the TRAM siRNA duplexes had no inhibitory effect on the dsRNA
response , while TRIF siRNA duplexes inhibited dsRNA-dependent RANTES induction
in agreement with published reports (88). As with RANTES, siRNA silencing of TRAM
prevented LPS , but not poly I:C , induction of the IP- I0 promoter (data not shown). These
observations confirm the studies with TRI and TRA dominant negative mutants and
demonstrate that both adapter molecules are required for full LPS/TLR4 signaling to IRF
target genes.
'W'
Discussion
The ability of individual TLRs to discriminate between invading pathogens is an
important determinant of the unique gene expression profies activated by different
microorganisms. While the specificity of microbe detection begins with the ligand
recognition features of one or more TLR, the discovery of a family of TIR-domain
containing adapter molecules , including MyD88 (106), Mal (16 , 17), TRIF (18 , 88), and
TRAM, suggest that the outcome of induced pathogen recognition also depends on the
TLR-restrcted utilization of these molecules, alone and in combination, to drve a
stimulus-specific response. The TLR3- and TLR4-restricted utilization of IR-inducing
adapter molecules such as TRAM and TRIF induces not only the cytokines, co-
stimulatory molecules , and anti-microbial peptides that are induced by all TLRs , but also
anti-viral tye I interferons and specific chemokines including IP- I0 and RANTES.
The dominant negative, siRNA, and protein:protein interaction data presented
herein demonstrate that TRAM is specifically required for LPS signaling, while TRIF is
required for signaling by both TLR3 and TLR4. Both MyD88 and Mal/TIRA also have
a role in more than one TLR. Thus , the activity of TRAM, unlike any of the other known
adapter molecules , may be restricted to a single TLR.
Defining the constituents of the TLR4 pathway activated by LPS has proven to be
a complicated process. First, it was believed that MyD88 was the only adapter molecule
needed for the full extent of the LPS response (59). However, data rapidly emerged that
showed that at least part of the LPS response also involves Mal/TIRP (66 , 89). Thus
both MyD88 and Mal/TIRAP are involved in LPS signal transduction but cannot account
for all, or even most, of the observed signaling traffc. The existence of TRAM and the
potential cooperativity of TRAM and TRI in the TLR4 pathway, may explain how
double MyD88/Mal-null cells are still capable of responding to endotoxin. It is intriguing
that the TLR4 pathway requires TRIF, TRA, MyD88 , and Mal/TIRAP while TLR3
signaling appears to require only TRIF. The gene expression profies activated following
dsRNA and LPS stimulation of cells , though similar, are not identical (124, 141). The
utilization of TRAM by TLR4 and not TLR3 may allow LPS/TLR4 to induce signaling
pathways and gene expression programs not possible by TLR3/TRIF-mediated signaling.
Thus , the combinatorial utilization of TRIF and TRAM by TLR4 may allow a specific
tailoring of the immune response to the pathogens that activate TLR4.
Both functional and direct biochemical studies indicate that the adapter molecules
used for the LPS response are interacting with one another as well as with TLR4. One
obvious question that needs to be addressed is how these tyes of observations, which
were made in a few types of transfected cell lines and primary bone marrow-derived
macrophages , apply to the myriad of cell types that respond to LPS. The response to LPS
is not uniform, an observation that is generally attributed to the cell surface density of the
LPS receptor components. But, simple receptor density clearly does not always explain
these differences and many different mechanisms are undoubtedly at work. Based upon
scanning electron micrographs of LPS exposed cells, it is likely that activated TLR4
forms a large ' signalosome ' involving multiple molecules of TLR4 (A.V. and D.
data not shown). The cytoplasmic face of the activated LPS receptor is likely to have a
large surface upon which these adapter molecules may sit. We propose that cell-specific
differences in the response to LPS may also involve differences in the number and the
composition of adapter molecules that assemble on TLR4. Co-crystallization of the
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cytoplasmic face of TLRs in complexes with the vanous adapter molecules or
combinations of adapter molecules wil be necessary to understand fully the physical
basis of how an activated TLR actually collaborates with these molecules to propagate an
intracellular signal. We predict that TRAM wil be a portion of a large platform of
adapter molecules bound to TLR4 upon which a variety of kinases and other molecules
can effectively function to initiate LPS responses.
While this manuscript was in preparation, Shu and colleagues reported on the
identification of TRAM, to which they gave the name TIR, as an adapter molecule that
interacts with the IL- , Mal, IRK and TRAF-6. These authors reported that
TRAM/TIR functions exclusively in IL- l signaling (21). In agreement with Shu and
colleagues , we have also detected TRAM in association with Mal (Fig. 3.4b), TRA6 and
the IL1RAcP (data not shown). Furthermore, we detected no inhibition of the IL1-
induced NF -KB response when cells were transfected with the TRAM -C 117H mutant
(Fig. 3.6). Since submission of this paper, two manuscripts have reported on the role of
TRIF in LPS signaling (60, 108). One of these manuscripts (108), postulates that there
may be another TLR4 adapter molecule, which was designated as " . Based on my
data, TRAM very likely represents " , although the precise mechanism whereby the
four known LPS adapters interact and contribute to MyD88-dependent and MyD88-
independent signaling remains to be determined.
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Figure 3. 1 LPS and dsRNA activate IRF3 and IRF7. (a) Bone marrow-derived
macrophages from wild-tye and MyD88-deficient mice were stimulated with LPS (0.
100 ng/ml), Malp-2 (5 nM) and dsRNA (1- 100 ug/ml) for 12 hours. The concentration of
RANTES was measured by ELISA. (b) Nuclear extracts were isolated from wild-type
and MyD88-deficient macrophages stimulated with LPS (10 ng/ml), Malp-2 (5 nM), and
dsRNA (50 mg/ml) for 1 h and subjected to EMSA using a 32 labeled ISRE consensus
sequence (ISG-15) as a probe. Activated complexes were visualized by autoradiography.
Activated ISRE DNA binding complexes were preincubated with polyclonal antibody to
IRF3 or two control antibodies prior to incubation with the ISRE probe (right panel). (c)
TLR3- and TLR4/MD2-expressing HEK293 cell lines were transfected with a luciferase
reporter gene containing the Gal4 upstream activation sequence and with 
Gal4 DBD
GaI4-IRF3 or Gal4 IRF7 (40 ng). After 24 h, cells were stimulated with LPS (10 ng/ml),
dsRNA (50 flg of poly I:C/ml), IL- lf3 (10 ng/ml) or left untreated for 8 hand luciferase
reporter gene activity measured.
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Figure 3.2 TRAM activates IRF3 and IRF7. (a) Alignent ofTIR domains of TRAM
TRIF, MyD88 and Mal with TLR1 , TLR2 , TLR3 and TLR4. The amino acid colors are
based on their physico-chemical properties where yellow = small, green = hydrophobic
turquoise = aromatic, blue = positively charged and red = negatively charged. (b)
HEK293 cells were transfected as in (c) above and cotransfected with 40 ng of TRAM or
TRIF. After 24 h, luciferase reporter gene activity was measured.
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Figure 3.3 TRAM interacts with IRF3 and CBP and signals via IKKt and TBK1.
(a) IR3-GFP-expressing HEK293 cells were plated on 35 mm glass-bottom sterile tissue
culture dishes and transiently transfected with 1 mg of Flag-tagged TRAM, TRIF
o,remptyvector and visualized 24 h later by confocal microscopy. (b) 293T cells were
transfected with 4 /lg of Flag-TRAM with or without a plasmid encoding IRF3
(untagged) as indicated. Twenty-four hours later, whole cell lysates were
immunoprecipitated with anti-IR3 , anti-Flag or anti-CBP and the immunoprecipitated
complexes immunoblotted for Flag-tagged TRAM and IRF3. Whole celllysates (WCL)
were also analyzed for Flag-tagged proteins. (c) HEK293 cells were transfected with the
RANTES luciferase reporter gene and TRAM (20 ng) and cotransfected with increasing
concentrations of IKKE-k38a, TBK1-k38a or IR3-DN from 10 , 20, 30 , 40, 60 , 80 ng.
Luciferase reporter gene activity was measured 24h after transfection.
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Figure 3.4 TRAM mediates the TLR4 pathway to IRF3 and IRF7. (a) HEK293 cells
were transfected with 40 ng of a RANTES reporter construct and cotransfected with
TRAM, TRAM-TIR, TRAM-C117H or TRAM-P116H. (b , c) TLR4/MD2- and TLR3-
expressing HEK293 cell lines were transfected with a luciferase reporter gene containing
the Gal4 upstream activation sequence and cotransfected with Gal4 DBD, Ga14-IRF3
Ga14-IRF7 or (d) the RANTES luciferase reporter gene as well as TRAM-C117H or
TRIF C as indicated. On the following day, cells were stimulated with LPS (10
ng/ml), dsRNA (50 Ilg/ml poly I:C) or left untreated for 8 hand luciferase reporter gene
activity measured.
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Figure 3.5 TRAM activates NF-KB and is specific to the TLR4 pathway. (a) HEK293
cells were transfected with 40 ng of an NF-KB reporter construct and cotransfected with
TRAM, TRAM-TIR, TRAM-C117H and TRAM-P116H. (b) TLR-expressing HEK293
stable cell lines were transfected with 40 ng of an NF-KB reporter gene and co-transfected
with increasing concentrations of TRAM-CI17H. One day after transfection, TLR-
expressing cells were stimulated with Malp-2 (2 nM), dsRNA (100 Ilg/ml poly I:C), LPS
(10 ng/ml), R-848 (10 mM), ILlf3 (10 ng/ml), TNF-a (10 ng/ml) or left untreated for 8 h
and luciferase reporter gene activity was measured.
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Figure 3.6 TRAM signaling requires the expression of TRIF. (a) HEK293 cells were
transfected with the RANTES luciferase reporter gene, TRAM or TRIF (40 ng) and
co-transfected with Flag-Mal , Flag-Mal-PI25H or Flag-TRIF. Whole cell lysates were
TRIF C or TRAM-C117H. Luciferase reporter gene activity was measured 24 h
later. (b) HEK293T cells were transfected with 4 /lg of TRAM-CFP or TRIF-CFP and
harvested 48h later, and immunoprecipitated with anti-GFP antibody (which also
immunoprecipitates cyan fluorescent protein; CFP or yellow fluorescent protein; YFP).
Immunoprecipitated complexes were resolved by SDS-PAGE and immunoblotted for
Flag-tagged adapters. Whole celllysates (WCL) were also analyzed for CFP- and Flag-
tagged proteins by immunoblotting. (c) Stable TLR4 YFP or TLR3 YFP -expressing HELA
cells were transfected with 4 /lg of plasmid encoding Flag-Mal, Flag-TRAM or Flag
TRA-C 117H. Fort-eight hours later, whole cell lysates were immunoprecipitated
with anti-GFP antibody and immunoprecipitated complexes immunoblotted for Flag-
tagged adapters. Western blotting of lysates demonstrates expression of stable TLRs and
transfected adapter proteins.
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Figure 3.7 TRAM and TRIF are required for RATES activation by LPS. (a) 293T
cells plated in 24-well plates were transfected with g of plasmids encoding TRA-
CFP , TRIF-CFP or Mal-CFP and cotransfected with 50 nM siRNA-TRAM or Lamin AlC
as indicated. 24h later, CFP fluorescence was measured by flow cytometry using a 405
TIm laser for excitation of CFP. The siRNA-TRAM nearly completely abolished
expression of the subpopulation of cells that express CFP. (b) U373/CD14 or TLR3-
expressing HEK293 cells were transfected with a RANTES reporter gene and co-
transfected with siRNA duplexes as indicated for 36 h. Cells were then stimulated for 8 h
with LPS or dsRNA and luciferase reporter gene activity was measured.
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CHAPTER IV:
The Myristoylation of TRIF-Related Adapter Molecule is Essential for Toll-Like
Receptor 4 Signal Transduction
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Abstract
TRAM is the fourth TIR domain-containing adapter to be described that
participates in TLR signaling. TRAM functions exclusively in the TLR4 pathway. Here
we show by confocal microscopy that TRAM is localized to the plasma membrane and
the Golgi apparatus , where it colocalizes with TLR4. Membrane localization of TRAM
is the result of myrstoylation since mutation of a predicted myristoylation site in TRAM
(TRAM -G2A), resulted in the dissociation of TRAM from the membrane and its
relocation to the cytosol. Further, TRAM, but not TRAM -G2A, was radio labeled with
H-myrstate in vivo. Unlike wild type TRAM, overexpression of TRAM-G2A failed to
elicit either IR3 or NF-KB signaling. Moreover, TRAM-G2A was unable to reconstitute
LPS responses in bone marrow-derived macrophages from TRAM-deficient mice. These
observations provide clear evidence that the myristoylation of TRA targets it to the
plasma membrane where it is essential for LPS responses through the TLR4 signal
transduction pathway, and suggests a novel manner in which LPS responses can be
regulated.
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Introduction
TLRs recognize microbial products derived from all the major classes of
pathogens and initiate a complex Immune response designed to eliminate invading
pathogens. A key structural motif involved in the signal transduction of TLRs is the TIR
domain (reviewed in (119)). TIR domains can be found in the cytoplasmic portions of all
TLRs and the IL- l receptor family, as well as a third subgroup ofTIR-domain containing
adapter proteins. The initial events of TLR signal transduction are thought to involve the
recruitment of pertinent adapter molecules, which in tu, provide a scaffold to enable the
recruitment and activation of additional signaling molecules. To date, four adapter
molecules have been associated with TLR signaling: MyD88 (15 , 142); Mal/TIRP(16
66); TRIF/TICAM- l(18 , 19 67); TRAM/TICAM-2 (20, 22 , 143) (all reviewed in
(144)). Exactly how the adapter molecules initiate signaling once a TLR is triggered by
its ligand is still unclear. This is particularly complicated in the case of TLR4, where all
four adapters are required for a complete LPS response.
LPS is the major constituent of the outer membrane of Gram negative bacteria
(145, 146). The recognition of LPS by host phagocytes stimulates the release of
inflammatory mediators and cytokines from a variety of target cells. In conjunction with
CD 14 and its co-receptor, MD- , TLR4 binds LPS and serves to elicit a "danger" signal
thus initiating the host immune response (for a complete review see (147). The
cytoplasmic face of TLR4 is quite unique amongst TLRs, as it utilizes all four TIR
domain-containing adapter molecules: MyD88 , Mal , TRIF and TRAM (148). In recent
years , considerable progress has been made delineating the requirement for each of these
adapter molecules in the TLR4-activated immune response. The recruitment of MyD88 to
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proximal TIR domains of activated TLRs allows for the interaction and activation of the
IRAK-family members, IRAKI and IRK4 (87 , 120), and the subsequent activation of
TRA-6 (121), a RIG finger domain-containing protein with ubiquitin ligase activity.
TAKI kinase, in turn, activates the IKK complex (149, 150), which phosphorylates
IKBa. This phosphorylation marks IKB for ubiquitination and degradation by the
proteosome. NF-KB is then released from IKBa, translocates to the nucleus , and regulates
NF-KB-dependent target genes including inflammatory cytokines. TLR4 also activates
the MyD88-independent responses that lead to the activation of IRF3 , the induction of
IFN- , and IFN-inducible genes, and the upregulation of co-stimulatory molecules (62
122, 148, 151). Mal/TIR appears to also regulate inflammatory cytokine genes
suggesting that Mal may co-operate with MyD88 to control these responses (16, 17 , 65
66).
Using an siRNA approach or gene targeting, several reports have suggested that
TRAM is uniquely required in the TLR4 signal transduction pathway and, together with
TRIF coordinates the activation of IRF3 and the MyD88-independent responses outlined
above (20, 67, 152, 153). The TRAM-TRIF module also controls MyD88-dependent
inflammatory responses suggesting that TRAM is a master regulator of both arms of the
TLR4 signaling pathway. Our earlier studies using overexpression systems (Chapter III)
suggested that TRAM functioned upstream of TRIF in TLR4 signaling (20). This
conclusion was supported by the observation that TRAM binds TRIF directly and recruits
it to TLR4 (22), as well as the observation that TRIF dominant negative constructs
eliminated the direct activation of the MyD88-independent pathway by TRAM, but not
r. .
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vice versa (22). In the case ofTLR3 signaling, where TRAM is not required, TRI binds
directly to the TLR3 TIR domain (19).
To characterize further the unique role of TRAM in the initiation of TLR4
signaling, we analyzed the subcellular localization of TRAM and the consequences of
TRAM localization for effcient signal transduction. Our study shows that TRAM is
localized to the plasma membrane and Golgi apparatus via N-terminal myrstoylation
where it co-localizes with TLR4. In fact TRAM contains a putative N-terminal
myrstoylation site, similar to that found in mammalian Src kinases (154). Mutation of
this predicted myrstoylation site (TRAM-G2A) leads to a redistribution of TRAM from
the plasma membrane to the cytosol. TRAM -G2A did not signal upon overexpression
and was unable to reconstitute LPS responses in macrophages deficient for wild-type
TRAM. These results indicate that myrstoylation and plasma membrane localization of
TRAM are critical for responses to LPS and indicate the potential for a hitherto
unappreciated mechanism of regulation of LPS responses.
. .
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Materials and Methods
Reagents. Unless otherwise stated, all reagents were purchased from Sigma Chemicals
(St. Louis, MO). E. coli 0111:B4 LPS was subjected to a second phenol extraction in
order to remove contaminating lipopeptides (49). Lipopeptides were purchased from
EMC Microcollections (Tuebingen, Germany).
Plasmids. Most of the constructs described in this paper have been described elsewhere.
These include: pCDNA3-TRAMcFP, pEF-BOS-TRAMFlag, pEF-BOS-TRA-C117H lag
pEF - BOS- TRIFFlag pCDNA3-MyD88CFP M yr YFP f3-(156);(20); (155);
galactosyltransferaseYFP (GolgiYFP) (57); NF-KB-luciferase, RANTES-luciferase, ISRE-
luciferase and Renilla-luciferase (20); the retroviral vector pMSCV2. IRS-GFP (157).
pCDNA3-TRAM-G2A and pEF-BOS-TRAM-G2A were generated by site directed
mutagenesis using a kit (Stratagene, CA). The plasmid pCDNA3-Fyn was subcloned by
PCR using cDNA obtained from E. Kurt-Jones (UMASS , MA); pCDNA3-Fyn-G2A was
generated by site directed mutagenesis. pMSCY2. IRES-GFP-murne TRA, murine
TRAM-G2A and murine TRAM-C117H were sub cloned from pEF-BOS vectors
expressing murine constructs. pCDNA3-T7-MyD88CFP was generated by PCR. The
packaging vector for the retroviruses was the proviral clone of Moloney Murine Sarcoma
Virus 'PEcu from O. Witte (UCLA , CA).
Cell lines. HEK293 cells stably expressing TLR2 YFP, TLR4 YFP and TLR9 YFP were as
described (57 , 155).
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Confocal Microscopy. HEK293 cells stably expressing TLR4YFP and TLR9YFP or Myr
YFP
were transfected with TRAcFP, TRAM-G2A CFP MyD88CFP, T7-MyD88CFP where
indicated. Twenty-four hours after transfection cells were imaged by confocal
microscopy using a Leica TCS SP2 AOBS microscope.
Subcellular fractionation. HEK293 cells stably expressmg TLR4YFP and TRAMcFP
TRAM-G2A CFP or MyD88CFP were seeded in 10 cm dishes at a density of 1 x 10 cells
per dish. Twenty-four hours later the media was removed, the cells were washed in PBS
and then scraped into fractionation buffer (20 mM Tris-HCl pH 7. , 10 mM MgCb, 
mM EDTA, 250 M sucrose, 200 M PMSF). The samples were subjected to 20 strokes
of a dounce homogenizer (Wheaton USA) and spun at 100 000xg for 1 h. The
supernatant (cytosolic fraction) was removed to a fresh tube and the pellet (membrane
fraction) was resupended in 50 l SDS sample buffer (50 mM Tris- , pH 6. , 10 %
glycerol (v/v) , 2 SDS (w/v) , 0.1 % bromophenol blue (w/v) and 5 
mercaptoethanol). The fractions were run on a 10 % SDS-PAGE gel, transferred onto
nitrocellulose and blotted with the appropriate antibody.
Luciferase reporter assay. Cells were seeded into 96-well plates at a density of 40 000
cells per well and transfected 24 h later with 80 ng of the indicated luciferase reporter
genes and the indicated amounts of the TRAM constructs , MyD88 or TRIF , using 0.
of GeneJuice (EMD Biosciences, CA) per well. The thymidine kinase Renilla-luciferase
reporter was also cotransfected (40 ng) in order that the data could be normalized for
transfection effciency. Cells were either left untreated or treated with LPS (1 g/ml) or
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Pam3Csk4 (2/lg/ml) as indicated for 6 hours. Cell lysates were then prepared, and
Radiolabeling. HEK293T cells were transfected using GeneJuice with the CFP-tagged
reporter gene activity was measured using the Dual Luciferase Assay System (Promega).
Data are expressed as the mean relative stimulation:t SD.
constructs as indicated. Eighteen hours post-transfection, cells were incubated in media
containing 250 /lCi of eH) myrstate for 4 hours. Cells were then lysed in .5 ml of lysis
buffer (20mM TRIS-HCL, 2 mM EDTA, 137 mM NaCl, 0.5% Triton X- lOO , glycerol
10%, with protease inhibitors). Polyclonal anti-GFP (Molecular Probes, OR) was
incubated with the cell lysates in protein- sepharose for 2 hours. The immune
complexes were precipitated and subjected to 4-15% SDS-PAGE. The gel was then dried
and developed using Amplify (Amersham, UK) according to the manufacturers
instrctions.
Reconstitution of bone marrow-derived macrophages. The retroviral vector pMSCV
expressing TRAM, TRAM-G2A, TRAM-C117H and GFP from the IRES element were
used to generate high-titer helper-free retroviral stocks (using the packaging plasmid
'PEcu) by transient co transfection of 293T cells (157). Twenty- four to seventy-two hours
later, cell supernatants were harvested, filtered and used to transduce target cells. BM-
derived macrophages were cultured from C57Bl6 mice or age- and sex-matched 
TRAM-
mice for 8- 10 days. Conditioned supernatant from L929 cells comprised 20% of the total
volume as a source of M -CSF. Cells were transduced with virus encoding the indicated
versions of TRAM or empty vector on day two , while cells were actively dividing. On
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day ten, cells were sorted for GFP and seeded into 96-well plates at a density of 35 000
cells per well. Cells were stimulated with LPS overnight after being allowed to receover
from cell sorting for 24h. Cell culture supernatants were analyzed for the presence of IL-
6 and RANTES by ELISA (R&D Systems , Minneapolis , MN).
cq'
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Results
Subcellular localization of TRAM
To further understand the role of TRAM in TLR4 signaling, we examined its
subcellular localization. Using a C-terminal CFP-tagged version of TRAM (TRAcFP
we discovered that in resting cells , TRAM resided at the plasma membrane and also in
the Golgi apparatus of HEK293 cells. Similar localization patterns were observed in
TLR4 YFP -expressing stable cell lines. TLR4 was expressed both at the cell surface as well
as localized to the Golgi apparatus , consistent with previous reports (57). In fact, TRAM
and TLR4 appeared to colocalize on the plasma membrane (Fig. 4. 1a. right panel
overlay). There was no co-localization of TRAM with TLR9 (Fig. 4. 1a), which resides in
the ER (155). In addition to the plasma membrane , TRAM appeared to localize in the
Golgi apparatus as seen in Figure 4. 1a (bottom). Cell fractionation studies in TRAM-
expressing HEK293 cells revealed that TRAM was exclusively found in the membrane
fraction in sharp contrast to the localization of MyD88 , which resided in the cytosolic
fraction (Fig. 4. 1b).
TRAM contains a putative myristoylation site
This localization pattern of TRAM in living cells indicated that TRAM was either
anchored to the membrane via direct interaction with a membrane-associated molecule
(such as TLR4) , by fatty acid modification, or both. To examine the possibility that
TRAM was anchored by acylation, we subjected the TRA sequence to N-
myrstoyltransferase (NMT) analysisprogram
(http://mendel.imp. univie.ac.at/myrstate/S UPLpredictor.html), which revealed that
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TRA contained a putative myrstoylation consensus sequence consisting of Met-GlyX-
Ser and Lys (Fig. 4.2a). Similar myristoylation sequences have previously been
To investigate if TRAM was indeed a myrstoylated protein, we took a number of
identified in members of the Src kinase family.
complementary approaches. We generated a mutant form of TRAM in which the glycine
at position 2 was mutated to alanine and examined its localization by confocal
microscopy. As a comparison, we compared the localization of MyrYFP, a synthetic
construct containing an acylation sequence derived from the mammalian Src kinase, Lyn
(156). MyrYFP was clearly membrane localized. In fact, M yr YFP and TRAMcFP co-
localized as indicated by the yellow overlay of the confocal image (Fig. 4.2b). Mutation
of glycine at position 2 to alanine (TRAM-G2A) resulted in the re-localization of TRAM
from the cell membrane to the cytosol (Fig. 4.2b). This was confirmed by sub-cellular
fractionation, with TRAM-G2A only occurrng in the cytosolic fraction (data not shown).
As a second approach, we compared the cellular localization of MyD88 , a TLR adapter
used by all TLRs except TLR3 , which localized to the cytosol (Fig. 4.2b). In contrast to
TRAM, MyD88CFP did not co-localize with MyrYFP. Next, we performed a "gain of
function" experiment and generated a mutant form of MyD88 , whereby the first 7 amino
acids of MyD88 were replaced with those from TRAM (T7-MyD88). This resulted in a
construct that, in theory, encoded a myrstoylated form of MyD88. T7-MyD88 was also
capable of localizing to the plasma membrane (Fig. 4.2c). Together, these results
suggested that the putative N-terminal myrstoylation site was sufficient for targeting
TRAM to the plasma membrane.
1..
-"... :,,
121
To determine further if TRA was a myrstoylated protein, we monitored
TRAM myrstoylation in vivo. HEK293T cells were transfected with wild type or G2A
mutant versions of TRAM, Mal, MyD88 or T7-MyD88. Cells were metabolically
labeled with eHJ myrstate. Fyn, a Src kinase family member involved in T cell receptor
(TCR) signal transduction , was used as a positive control for myrstoylation. Likewise
Fyn G2A served as a negative control for the incorporation of eHJ myrstate. The
indicated proteins were transfected into HEK293T cells , immunoprecipitated with anti-
GFP, run on an SDS-PAGE gel, and examined for incorporation of eHJ myrstate 
autoradiography (Fig. 4.3). TRAM, but not TRAM-G2A, was clearly myrstoylated 
vivo. Furthermore, neither Mal nor MyD88 were labeled with eHJ myrstate. In contrast
T7-MyD88 effciently incorporated eHJ myrstic acid. These results provided clear
evidence that TRAM was indeed a myrstoylated protein. Despite the fact that TRAM
and Mal have similar molecular weights , 232 and 235 amino acids, respectively, these
two adapters resolved differently on SDS-PAGE (Fig 4. , lower panel), possibly due to
different post-translational modifications.
TRAM-G2A does not signal upon overexpression
As previously reported, transient expression of TRAM induced both NF-KB and
IRF3 dependent reporter activation in HEK293 cells (20). Furhermore , mutation of the
cysteine residue in the predicted TIR domain BB loop of TRAM, at position 117
(TRAM-CI17H), a mutation equivalent to the C3H1HeJ mutation in the TLR4 TIR
domain BB loop, abolished the ability of TRAM to signal (20). To determine if TRAM-
G2A was compromised in its ability to signal upon overexpression, we monitored the
!.;:"
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ability of TRAM-G2A to induce NF-KB or IR3-dependent reporter gene activation in
HEK293 cells. Wild-type TRAM, but neither the C 117H nor the G2A mutant could
drve NF-KB or RATES reporters (Fig. 4.4a and b). Moreover, TRAM-G2A modestly
inhibited LPS-induced IRF3 reporter gene induction, while wild-tye TRAM potentiated
this response (Fig 4.4c). Similar results were obtained when LPS-induced NF-
activation was examined in cells transfected with TRAM, or the TRAM mutants (Fig
4.4d). As anticipated, TRAM-G2A had no effect on lipopeptide- induced NF-
activation in TLR2 expressing HEK293 cells (Fig. 4.4e). We also examined the ability 
TRAM-G2A to interfere with signaling by other TIR adapters. For example, transient
expression of MyD88 induced NF-KB reporter gene expression, as was also true in the
case of TRAM and TRIF , albeit to a lesser extent. TRAM-G2A had no effect on either
MyD88- or TRIF-induced NF-KB activation, but inhibited the activation of NF-
induced by overexpressing wild-type TRAM (Fig. 4.4f). These results suggested that
TRAM-G2A cannot signal effciently and, in fact, can act as a dominant negative
interfering mutant. Together, these results suggested that the membrane localization of
TRAM was critical for its ability to initiate efficient signaling.
Myristoylation of TRAM is critical for LPS responses in macrophages
To investigate if membrane localization of TRA was critical for LPS responses
in vivo we reconstituted bone marrow-derived macrophages from TRAM-deficient mice.
To this end, we generated retroviruses expressing either wild type TRAM, TRAM-G2A
or TRAM -C 117H in tandem with an internal ribosomal entry site (IRES)-encoded GFP.
This construct was designed to allow for the expression of a bicistronic mRNA that
Oi.
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would give rise to the translation of TRAM at a 1: 1 molar ratio with GFP. Transduced
bone marrow-derived macrophages from TRAM-deficient mice were sorted by flow
cytometry for GFP fluorescence. As seen in Figure 4.5a
, the level of GFP fluorescence
and hence TRAM reconstitution, was comparable in the cells transduced with either the
wild-type TRAM, the TRAM-G2A, or the TRAM-CI17H retroviruses. We were unable
to detect TRAM or the mutants in transduced and GFP-sorted cells with Western blotting,
presumably because of the relatively low-level expression of TRAM from the construct
in these cells (data not shown). However, when we compared the expression level of the
three proteins in transfected HEK293 cells, we found no significant difference in
expression levels. We therefore believe that the levels of the wild type TRA and the
mutants were similar.
Wild-type or TRAM knockout macrophages transduced with an IRES vector that
encoded only GFP were also sorted for productive infection (data not shown). The CC-
chemokine RANTES is a downstream target gene of the MyD88-independent pathway
following LPS stimulation (20). IL-6 production in response to LPS was reported to be
severely abrogated in TRAM-deficient macrophages (143). Therefore, we examined IL-
and RANTES production following LPS stimulation of wild-type and TRAM -deficient
macrophages that had been transduced with either the control vector-expressing
retrovirus or the TRAM-expressing retroviruses. As seen in Figure 4.
, GFP-positive
wild-type, empty vector-expressing macrophages produced IL-6 and RANTES following
LPS stimulation, while GPF-positive, TRAM-deficient, empty vector-expressing
macrophages failed to induce either IL-6 or RANTES under identical experimental
conditions. Remarkably, TRAM-deficient macrophages transduced with a virus encoding
124
the wild-type TRAM completely restored responsiveness to LPS challenge. As predicted
TRA-C 117H was unable to restore LPS responses , consistent with our earlier in vitro
studies. Importantly, TRAM-G2A was also incapable of restoring LPS responses (Fig.
5b). Cells transduced with the TRAM-G2A mutant were unable to produce either
RANTES or IL-6 in response to LPS challenge. These results provide clear evidence that
the myrstoylation and subsequent membrane localization of TRAM was critical for
responses to endotoxin.
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Discussion
A diverse range of viral and cellular proteins are known to be covalently modified
by lipophilic moieties, including protein kinases
, guanine nucleotide binding proteins
transmembrane receptors, and viral structural proteins (reviewed in (158)). The
attachment of lipid groups to these molecules influences protein-protein interactions
membrane binding affinity and cellular signal transduction. Here we provide the first
evidence that the TIR domain-containing adapter molecule, TRAM, is colocalized with
TLR4 at the plasma membrane as the result of myrstoylation and our findings implicate
fatty acid modification as a critical event in TLR4 signaling.
Because TRAM does not contain a signal peptide sequence, its presence on the
membrane could be the result of either protein:protein interactions , prenylation or fatty
acid modification. TRAM does not contain a predicted prenyl modification site as it does
not contain a CAA box at or near its C-terminus. There are two distinct types of fatty
acid modification: myrstoyl and palmitoyl (154, 158 , 159). In this study, we identified in
TRA a putative N-terminal myrstoylation sequence. For myrstoylation to occur, the
initiating methionine is usually removed by methionine amino peptidase during
translation and the glycine at position 2 becomes the N-terminal amino acid. The
requirement for glycine at the N-terminus is absolute; no other amino acid can substitute.
Such proteins are labeled with myrstate on these N-terminal glycines in an irreversible
co-translational manner by N-myrstoyl transferase. This type of covalent modification
occurs in many signal transduction components and is central to their function (154). 
well-characterized myristoylated protein is the Src kinase pp60v-src from Rous sarcoma
virus. A myristoylation mutant of this Src kinase (G2A) does not bind to the membrane
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and is incapable of mediating cellular transformation (154). Myrstoylation is also
required for membrane association and virion formation by Gag polyproteins of
mammalian C- and D-type retroviruses. Non-myristoylated mutants of murine leukemia
C virus Pr65gag and HIV- l Pr55gag are predominantly cytosolic, and infectious viral
particles are not produced (160).
Although myrstoylation is clearly necessary for membrane binding of N-
myrstoylated proteins, myrstoylation alone is not sufficient to confer stable membrane
most often either palmitoylation or the presence of a polybasic cluster of amino acids.
binding properties to proteins (161). It is thought that a second signal within the N-
myrstoylated protein is required for effcient membrane binding. The second signal is
The latter is the mechanism used by the Src kinase pp60v-src for membrane anchoring
(154, 159). A basic amino acid cluster in Src kinase, downstream from the glycine at
position 2 , forms electrostatic interactions with acidic phospholipid headgroups in the
membrane. At present, it is unclear what the natue of the second signal that tethers
TRAM to the membrane might be. TRA has a number of lysine residues close to the
myrstoylation site, which may serve as a polybasic cluster. A combination of both
myrstate and basic motifs in TRAM would allow the hydrophobic and electrostatic
forces to synergize and facilitate membrane binding (161). TRAM also has a number of
cysteine residues, however, which could potentially become palmitoylated. A third
possibility for membrane tethering might involve association with membrane anchored
molecules, which in the case of TRAM could be TLR4. This latter explanation seems
less likely, as when TRAMcFP was transfected into HEK293 cells , which ordinarily lack
expression of TLR4, TRAM localization to the cell surface and Golgi were observed
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nevertheless (data not shown). Of course, other cell surface TLRs are theoretically
capable of serving this function, but cells from TRAM-deficient animals appear to have
normal responses to a variety of TLR ligands, including those for TLR2, TLR5 , TLR 7
and TLR9 (data not shown), suggesting that TRAM selectively binds to the cytoplasmic
domain ofTLR4.
Proper localization of signaling molecules to specific cellular membranes is
critical for their function. It is tempting to speculate that clustering of myrstoylated
proteins into specialized membrane microdomains, such as lipid rafts or caveolae
enhances particular protein-protein interactions important for subsequent signal
transduction. LPS has been reported to result in the redistribution of TLR4 into lipid rafts
(162). Acylation of TRAM might aid in this redistribution. Similarly, in the case of
TRAM, co-localization with TLR4 in lipid rafts may be critical for signaling.
A key question that remains to be answered is why TRAM must be constitutively
surface localized at the plasma membrane in order to allow cells to signal through TLR4.
One possible explanation is that membrane-localized TRAM must leave the membrane
and dissociate from TLR4 in order to propagate signals downstream. Indeed, preliminary
experiments suggest that TRA leaves the membrane after LPS stimulation. In this
scenario , the dissociation of TRAM from the membrane could be a regulated event (e.
de-myrstoylation, de-palmitoylation, or phosphorylation). N-myrstoylation is usually a
permanent modification. However, there is evidence in particular situations
g., 
brain
synaptosomes, that a de-myrstoylase activity modifies myristoylated MARCKS
promoting its release form the membrane (163). De-palmitoylation is a more common
mechanism of protein translocation because the thio-ester linkage between palmitate and
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the polypeptide is quite labile. Another possible mechanism involves protein
phosphorylation. Electrostatic interactions between polybasic residues and phospholipids
headgroups could be destablized by phosphorylation events adjacent to polybasic
clusters. Ligand induced phosphorylation of TRAM could potentially elicit its
dissociation from the membrane. Recent evidence from O' Neill and colleagues suggest
that TRA is indeed phosphorylated by protein kinase C epsilon (PKCE) following LPS
signaling. Myrstoylated proteins are often phosphorylated by PKC near their N-termini
leading to their dissociation from the membrane (164- 167). Phosphorylation of TRAM by
PKCs is critical for LPS signaling (O'Neill personal communication), consistent with the
possibility that TRAM phosphorylation could facilitate it to leave the membrane
following LPS signaling.
In conclusion, the data described herein shows that TRAM is the only adapter in
TLR signaling to be myristoylated, conferrng upon it membrane localization that is a
prerequisite for LPS signaling. Defining the functional significance of membrane-
localized TRAM in LPS signaling remains to be completely elucidated, but the data
strongly suggest that the acylation of TRAM is one means by which cells regulate their
responses to bacterial endotoxin.
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Figure 4.1 TRAM is associated with the cell membrane. a. Stable TLR4YFP-or
TLR9 YFP -expressing HEK293 cells were transiently transfected with TRAMcFP . Twenty-
four hours after transfection, cells were visualized by confocal microscopy. b. Membrane
fractionation was carried out on HEK293 cells stably expressing TLR4 YFP and either
TRAMCFP or MyD88 cFP. The fractions were resolved on a 10% SDS-PAGE gel prior to
transfer to nitrocellulose and immunoblotting.
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Figure 4.2 TRAM contains a putative myristoylation sequence. a. Comparison of the
consensus sequence for protein N-terminal myrstoylation to amino acids 1- 18 of TRAM.
Blue characters indicate amino acids that match myrstoylation consensus sequences. 
MyrYFP stable HEK293 cells were transiently transfected with TRAMcFP or TRAM-
G2A CFP and visualized by confocal microscopy. c. MyrYFP stable HEK293 cells were
transiently transfected with MyD88CFP or T7-MyD88CFP and visualized by confocal
microscopy 24 hours later.
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Figure 4. TRA is myristoylated in vivo. HEK293T cells were transiently transfected
with CFP-tagged versions of the indicated constructs. Eighteen hours after transfection
cells were incubated in media containing 3H myristic acid (250 IlCi/well) for 4 hours.
Cells were lysed, immunoprecipitated with anti-GFP polyclonal Ab, and immune
complexes resolved by SDS-P AGE , followed by autoradiography. Whole cell lysates
were immunoblotted with anti-GFP mAb.
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Figure 4.4 TRAM-G2A fails to activate the RATES promoter and NF-KB. a and b,
HEK293 cells were transiently transfected with the RANTES , NF-KB , or ISRE luciferase
reporters as indicated. Flag-tagged versions of TRAM , TRAM-G2A, and TRAM-C117H
or empty vector were cotransfected as indicated. c d and e TLR2- or TLR4/MD2-
expressing HEK293 cells were transfected as indicated and 24 hours later were
stimulated with LPS (2 Ilg/ml) or Pam3Csk4 (2 Ilg/ml) for 6 hours. f, 
HEK293 cells were
transfected with the NF-KB-luciferase reporter and cotransfected with wild-type TRAM
TRIF , or MyD88 in the presence or absence of TRAM-G2A, as indicated. In all cases
the thymidine kinase Renilla-luciferase reporter was used to control for transfection
efficiency. Twenty-four hours after transfection, cell lysates were generated and
luciferase activity was assayed. All the data are representative of three independent
experiments.
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Figure 4.5 TRAM myristoylation is critical for optimal LPS responses. a. Bone
marrow-derived macrophages from C57BL/6 or TRAM-/- mice were cultued in 20%
conditioned supernatant from L929 cells as a source of M-CSF. On day 2, cells were
transduced with viral supernatant derived from either empty vector, WT TRA, TRAM-
G2A, or TRAM-CI17H viral constructs. On day 10, cells were sorted for GFP and
seeded in 96-well plates at 40 000 cells/well. Transduced and GFP-sorted cells were
examined for GFP fluorescence by F ACS analysis. GFP-positive cells were stimulated
with LPS as indicated, and cell supernatants were assayed for IL-6 and RANTES by
ELISA.
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CHAPTER V:
DISCUSSION
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The results of my Ph.D. studies have provided insights into the molecular signal
transduction pathways of the innate immune system. In particular, my work has focused
on the regulation of the IRF3-dependent innate immune response. Chapter 2 focused on
the identification of IKKE and TBKI as key regulators of the IR3 activation pathway.
Importantly, these kinases serve as a point of convergence for different pathways
activating on the same transcriptional regulator. TBKI is common to both the anti-viral
response and the LPS response. Chapters 3 and 4 focused on the characterization of a
new molecular player in the IR3 response, TRAM, which is a critical component of the
LPS/TLR4 signaling cascade. Elucidating the roles of IKKE, TBK1 , and TRAM in these
signal transduction pathways may provide new targets for drg intervention. This could
lead to new cures or treatments for both pathogen-borne illnesses and autoimmune-
related diseases.
Viral infection leads to the induction ofIFNa/p. Specifically, this has been shown
for a variety of viral families, including both RNA and DNA viruses. Hosts have
developed a variety of ways to detect viral infection. As discussed in the introduction
both TLRs and RNA helicases have a role in this detection. As a result, the subsequent
activity of type I IFNs is crucial in controlling the spread of the infection (reviewed in
(168)). In fact, viruses attempt to inhibit the induction oftype I IFN in a number of ways
most of which are unkown (reviewed in (169)). For example, the NS3/4A protease of
hepatitis C virus can cleave TRIF, resulting in a blockage of IFN production upon
infection (170). Thus , understanding the signals and pathways that lead to the induction
of type I IFN is critical to understanding viral pathogenesis. The TLR4 agonist LPS also
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induces type I IFN. It seems plausible that bacteria have also evolved ways to combat the
induction of the IFN response although, to date, no such mechanism has been reported.
The identification of the kinases responsible for phosphorylating IR3 increases
our understanding of the IFN response. The work ilustrated in this dissertation suggests
that TBKI and IKKE are key kinases involved in the signaling pathways leading to the
transcription of IFNf3. A key question that remains is the relative contribution of these
two kinases in the immune response to different bacteria and viruses. Since the
completion of these studies , Akira et al. and Cheng et al. have made an effort to analyzed
the requirement of the kinases in innate immunity by studying cellular responses of either
singly- or doubly-deficient mice (171 , 172). It appears that TBKI is the predominant
kinase in TLR3- and 4-mediated IFN responses , while both kinases have roles in virus-
mediated IFN responses, at least in embryonic fibroblasts from doubly-deficient mice
(172). Due to the embryonic lethality of TBKI deficient mice, the generation of
IKElTBK1-deficient mice under a TNFa deficient background is needed to analyze the
relative roles of these kinases in various cell types as well as in the whole organism.
TLRs 7, 8 and 9 also induce antiviral responses. However, these responses are
primarily mediated through IFN a. Transcription of IFN a requires the activation of IRF7.
Hiscott et al. reported that IKE and TBKI could phosphorylate both IRF3 and IR7
(70). Do either IKKE and/or TBKI playa role in IFNa induction through TLRs 7, 8 , and
9? It appears that the answer to this question is no. Akira et al. showed that TLR9-
induced IFNa production is not abrogated in cells from either IKKE- or TBK1-deficient
mice (173).
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The continued research of TLRs has revealed a complex network of signal
transduction pathways. Some of these pathways are shared by all TLRs , while others are
unique to just a few. Activation of TLRs is thought to occur through the dimerization
and/or clustering of TLRs upon engagement with cognate ligand. This occurs thr TIR-
TIR interactions. The next step is the recruitment of TIR domain containing adapter
molecules. TLR4 is unique among the TLRs in that it utilizes four TIR domain-
containing adapter molecules: TRA , TRIF, Mal, and MyD88. The signaling cascade of
TLR4 has often been described as consisting of two distinct pathways and readouts based
upon the involvement of MyD88. Historically, the MyD88-dependent pathway was
ascribed the function of inducing pro-inflammatory cytokines such as TNF -a and IL-6. In
contrast, the MyD88-independent pathway was attributed to the activation of IRF3 and
induction of IFNf3. This simple dissection of the LPS/TLR4 signaling pathway is
incorrect, especially concerning pro-inflammatory cytokine induction. The phenotype of
Mal and MyD88 deficient macrophages is similar in terms of LPS signaling (59, 65).
Both Mal and MyD88 deficient macrophages are deficient in pro-inflammatory cytokine
induction but are stil capable of IRF3 activation/IFNf3 induction. Conversely, TRAM
and TRIF deficient macrophages are defective in IR3 activation/IFNf3 induction upon
LPS stimulation. An often-overlooked phenotype of TRAM and TRIF deficient mice is
their inability to induce pro-inflammatory cytokines in response to LPS as well. Thus
there is a clear distinction between the two arms of the pathway concerning IRF3
activation/IFN induction but it appears that both arms are important for pro-
inflammatory cytokine induction. Moreover, a recent study by Thomas et al. ilustrates
the importance of IFNf3 for normal MyD88-dependent gene expression. Specifically,
!f"
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IFNW macrophages exhibit diminished basal levels of essentially all MyD88-dependent
genes examined (submitted).
Another important observation made from these TIR domain-containing adapter
knockout mice is the detection of two distinct phases of NF-KB activation upon LPS
stimulation. Mal and MyD88-deficient macrophages display a delay in NF-KB activation
1O-20 minutes). A different phenomenon can be seen with both TRAM- and TRIF-
deficient macrophages (60, 153). TRAM and TRIF knockout macrophages have a normal
early phase NF-KB activation. However, they are deficient in activating NF-KB during
later time points ( 20-45 minutes). Thus , it appears that Mal and MyD88 coordinate the
early phase NF-KB activation while TRAM and TRIF coordinate the late phase NF-KB
activation. Either of these phases alone is enough to induce TNF-a mRA message but is
insufficient to produce detectable amounts of TNF-a protein (K.A.F personal
communication). Thus, a sustained NF-KB (0-45 minutes) activation provided by both
MyD88-dependent and -independent pathways seem to be required for the optimal
production ofTNF-a protein and other pro-inflammatory cytokines.
Recently, Baltimore et al. (174) described a possible mechanism for the
observance of these two phases ofNF-KB activation. In this model, the activation ofIR3
leads to the induction of small amounts TNF -a. Autocrine signaling through the TNF
receptor then accounts for the late phase of NF-KB activation. These studies also
indicated that the late phase NF-KB activation was dependent upon protein synthesis and
independent of TRAF6. This model, if correct, would then predict that the induction of
other pro-inflammatory cytokines such as IL-6 and IL- 12 in response to LPS would be
I.;
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entirely dependent upon TNF -a expression. This specific aspect of the model has yet to
be tested.
Another interesting aspect of the LPS/TLR4 signal transduction pathway is the
requirement of four TIR domain-containing adapters. Exactly how these adapters
assemble onto LPS-induced ligated TLR4 molecules is unkown. Moreover, the nature of
the stoichiometry of the activated TLR4 receptor is not presently known. Is the active
receptor simply a homodimer or an aggregated complex of multiple TLR4 molecules?
The latter is supported by scanning electron microscopy studies suggesting that a huge
signalsome forms shortly after TLR4 stimulation in HEK/TLR4/MD-2 cells (36).
Co-immunoprecipitation assays can reveal associations of molecules in a
complex. However these associations are often not indicative of direct binding. A
superior approach is yeast two-hybrid. A positive readout from data collected from yeast
two-hybrid relies upon the direction interaction between two proteins. Several groups
have performed yeast two-hybrid studies involving the TIR domains of TLR3 and 4 in
combination with the adapter proteins. These data are summarized in Table 5. 1 (16, 19
22). Results from these studies indicate that TRAM can interact with both the TIR
domain ofTLR4 and TRIF. In contrast, TRIF does not directly bind to the TIR domain of
TLR4. Unfortnately, there is no published yeast two-hybrid data concerning interactions
of either MyD88 or Mal with the TIR domain of TLR4. Confocal studies of fluorescently
tagged adapters performed by our lab indicate that TRA (Fig. 4. 1) and Mal (see Fig.
1) localize to the membrane ofHEK293 cells , while MyD88 (Fig. 4.2) and TRIF (data
not shown) appear to be cytosolic. These data support a hypothesis where Mal serves to
recruit MyD88 to the plasma membrane while TRAM serves to recruit TRIF to the
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plasma membrane upon activation of TLR4 (16, 19 , 175). Hence , TRAM and Mal may
play the role of bridging adapters while MyD88 and TRIF may act as signaling adapters
in TLR 4 signal transduction.
Preliminary research was undertaken to determine the membrane binding
mechanism of Mal. Using a confocal approach , the membrane binding activity could be
attributed to the first 74 amino acids of Mal (N-term Mal). Analysis of this N-terminal
region of Mal revealed two stretches of positively charged lysines and arginines (region
A (12-20); region B (30-36)). Replacement of these charged amino acids with asparagine
either alone or in combination (AB- Mal), resulted in a Mal construct that no longer
displayed membrane localization properties, as seen by confocal microscopy (Fig. 5. 1).
These two charged regions could interact with the negative charge of the inner leaflet of
the plasma membrane to facilitate membrane binding of Mal.
During the preparation of this dissertation, Medzhitov et al. reported that Mal
contains a phosphatidylinositol 4 biphosphate (PIP2) binding domain (176). The PIP2
binding domain was localized to the first 40 amino acids of MaL Specifically, mutation of
lysines 15, 16, 31 and 32 to alanines (Mal 4x) abolished membrane binding of Mal.
Interestingly, these four lysines are present in the two regions defined in Figure 5.
Much like the inability of TRAM G2A to reconstitute LPS responses in TRAM-deficient
macrophages , Medzhitov et al. showed that Mal 4x was incapable of reconstituting LPS
responsiveness in Mal-deficient macrophages. The authors hypothesized that the main
function of Mal was to recruit MyD88 to PIP2-containing membranes. This was
experimentally tested by reconstituting Mal-deficient macrophages with a version 
MyD88 that was capable of binding PIP2 on the cell surface. Indeed, a MyD88 construct
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with a phospholipase C PIP2 binding domain attatched at the C terminus was capable of
reconstituting LPS responses in both MyD88 and Mal-deficient macrophages. Taken
together, these observations suggest that the main function of Mal is to recruit MyD88 to
PIP2-containing membranes where it can interact with TLR4. It would be interesting to
test whether an analogous situation occurs with the interaction of TRAM and TRIF. First
does TRAM localize to a particular micro-domain of the membrane? Moreover, can a
membrane-localized version of TRIF reconstitute LPS responses in TRA- or TRIF-
deficient macrophages?
Again, given the yeast two-hybrid data in Table 5. 1 (e. , neither TRAM nor
TRIF directly bind to either Mal or MyD88) and the subcellular localization data one can
speculate that a single homodimer ofTLR4 can accommodate a TRAM-TRIF interaction
as well as a Mal-MyD88 interaction, as detailed in Figure 5.2. If this is the case, are these
two pathways separate signaling events or are they linked somehow? To determine
unequivocally the relationship of the adapters and TLR4, co-crystallization of the
cytoplasmic portion of TLR4 with the adapter molecules is needed. Another less
technical approach could be to perform overexpression/dominant negative experiments
similar to Figure 3.6. For example, we can ask whether a TRIF or TRAM dominant
negative can block the activation of NF-KB by Mal or MyD88 overexpression. Results
from these types of experiments may answer the question of whether the two pathways
are linked or separated.
Over the last decade, lipid rafts have gained significant attention in the field of
signal transduction (177). Upon ligand binding, cell-surface receptors and their associated
intracellular signaling molecules are thought to enter lipids rafts thus creating distinct
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receptor clusters , which provide stable focal points for cellular activation (177). The LPS
receptor appears to follow this hypothesis. LPS treatment of HEKlTLR4/MD-2 cells
results in the aggregation of TLR4 on the cell surface as seen by scanning electron
microscopy (36). Furthermore, Triantafiou et al. (162) showed that TLR4 and MyD88
are recruited to lipid rafts in a LPS-dependent manner. In addition, pretreating cells with
raft-disrupting drgs, such as nystatin, significantly inhibited LPS- induced TNF-a
secretion (162). Thus , it appears LPS/TLR4 signal transduction involves lipid rafts. As
previously indicated both TRAM and Mal localize to the plasma membrane through
myrstoylation and PIP2 binding sites, repectively. As discussed in Chapter IV, the
hypothetical second signal that localizes TRAM to the membrane is not known. In
addition to myrstoylation, TRAM could become palmitoylated. This dual acylation of
TRAM could result in its localization into lipid rafts and be a requirement for LPS/TLR4
signal transduction. Further examination of the membrane localization mechanism of
TRA will answer many questions related to LPS/TLR4 signal transduction (see below).
Other important questions remain. For instance, why does TRAM need to be
localized to the plasma membrane and not simply have the ability to be recruited as is the
case with MyD88? A clue to the answer of this question may be the apparent role of
Protein kinase C epsilon (PKCE) in LPS/TLR4 signal transduction (178). Quiescent PKC
isoforms normally reside in the cytosol of resting cells. Upon activation, as in the case of
phorbol 12- myristate 13-acetate (PMA) stimulation, PKC translocates to the cellular
membrane where is phosphorylates relevant substrates, some of which are myristoylated
proteins. For example, Myrstoylated Alanine-rich C Kinase Substrate (MARCKS) is a
myristoylated protein that is phosphorylated by PKC isoforms (179, 180).
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PKCE has been shown to playa key role in the immune-detection of the Gram
negative bacterial product LPS (178). However, the target for PKCE in LPS/TLR4
signaling is unkown. In collaboration with Luke O'Neil (Trinity College, Dublin
Ireland), we have found that TRA is transiently phosphorylated by PKCE on Serine 6
and 16 in an LPS-dependent manner. Activation of IRF3 and induction of the chemokine
RANTES , which are both TRAM-dependent, were attenuated in PKCE-deficient cells
(data not shown). Furhermore TRAMS 16A which eliminates the PKCE
phosphorylation site, is inactive when overexpressed and is attenuated in its ability to
reconstitute signaling in TRAM-deficient cells. Collectively, these observations suggest
that TRAM is a target of PKCE in LPS/TLR4 signal transduction, thus identifying a key
therapeutic target for ameliorating conditions of bacterial sepsis.
PKC8 mediated phosphorylation of MARCKS results in the translocation of
MARCKS from the plasma membrane to the cytosol (181). This event occurs through the
disruption of a region of positively charge amino acids by the negatively charged
phosphate group. This process , called and "electro-static switch", is crucial for the
activity of MARCKS (181). No equivalent stretch of positively charged amino acids can
be seen in the primary amino acid sequence of TRAM. However, upon three-dimensional
folding, TRA may contain an equivalently charged area. Phosphorylation of TRAM on
serines 6 and 16 may result in a destabilization of TRAM in the membrane and result in
its relocation into the cytosol. This scenario would dramatically alter the current views of
LPS/TLR4 signal transduction. Instead of an adapter complex as ilustrated in Figure 5.2
activated TRAM, and presumably TRIF , would dissociated from the active TLR4
receptor into the cytoplasm to either propagate or deactivate the signal.
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In conclusion, continued research in the area of innate immunology holds the
promise to identify many novel proteins and pathways that could someday be useful in
the development of specific immuno-modulating therapies. Indeed, many pharmaceutical
companies and academic laboratories are making progress in this area. Future therapies
may be quickly realized in the decades to come with the advent of new technologies and
the deciphering of the human genome. It is my hope that the research performed herein
adds to the knowledge of our species.
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Figure 5. Positively charged regions within the N-terminus of Mal faciltate
membrane localization. a. The N-terminus of Mal (amino acids 1-74). Amino acids
shown in green represent positively charged amino acids. Region A (12-20); Region B
(30-36). b. Confocal analysis of various MalcFP fusion constructs. Full-length Mal and the
terminus of Mal (a.a 1-74) localize to the membrane in HEK293 cells. Replacement of
the charged residues in both regions A and B both alone or in combination (AB- MalcFP
with alanine results in a cytoplasmic localization of Mal.
Figure 5.
MASSTSLPAP GSRPKKPLGK MAWFQTLL
KKPKKPNSP ESTSSDASQP TSQDSPLPPS
LSSVTSPSLP PTHA
MalCFP term MalcFP AB-MaICFP
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Figure 5.2 The potential arrangement of the TIR adapters on an activated TLR4
homodimer. A hypothetical adapter complex consisting of two separate modules on an
LPS activated homodimer: a TRAM-TRIF module binding to one side of the TLR4
homodimer interface; a Mal-MyD88 module binding to the second TLR4 homodimer
interface.
;;.
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Table 5.
TRAM Mal MyD88 TRIF TLR4
TRAM Yes Yes Yes
Mal Yes Yes
MyD88 Yes Yes
TRIF Yes Yes
TLR4 Yes
Yeast two-hybrid interactions among adapter molecules and TLR4
(16, 19, 22). ND= No Data.
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